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1. Introduction 
 
1.1 Cadherins 
 
Cadherins are a large superfamily of transmembrane glycoproteins that mediate calcium-dependent 
homophilic cell-cell adhesion. Cadherins are expressed by most organisms from unicellular 
choanoflagellates to most complex vertebrates, and they are usually located at cellular adherent 
junctions. In addition to their pivotal role in mechanical adhesion between the cells, cadherins have 
multiple functions in tissue morphogenesis, cell recognition and sorting, regulated cell motility and 
the induction and maintenance of tissue/cell polarity (1). Cadherins play a vital role in formation 
and maintenance of diverse tissues and organs such as polarization of very simple epithelia, 
mechanical linkage of hair cell to cochlea (2), and provision of an adhesion code for neural circuit 
formation during wiring of the brain (3). Thus, malfunctioning of mechanisms regulating cadherin 
expression levels or their functionality adversely affects tissue architecture and tissue cellularity, 
eventually resulting in tissue diseases. 
 
Structural diversity within the cadherin superfamily enables an assortment of cell interactions and 
tissue morphogenic processes. Variations in structure, along with temporal and spatial 
transcriptional regulation in cadherin subtype facilitate interactions that differentially modulate 
cadherin activity and intercellular signaling responses to adhesion (1). In spite of their structural 
diversity, members of the cadherin super family typically possess N-terminal tandem repeat 
extracellular cadherin domains (EC domains) that contain a cadherin-specific motif. Although the 
number of EC domains may range from 5 to 34, each EC domain comprises about 110 amino acids 
and connections between these domains are rigidified by specific binding of three Ca2+ ions (4). 
This Ca2+ binding is essential for adhesive function of cadherins, hence the derivation of their name 
- Calcium dependent adherent protein. Typically cadherins also possess a transmembrane domain 
and a cytoplasmic domain. Interactions of the cytoplasmic domain with intracellular molecules vary 
between cadherins; for example classical cadherins interact with catenins and actin cytoskeleton 
where as desmocollins interacts with intermediate filaments (Fig. 1). T-cadherin is an atypical GPI 
anchored cadherin, possessing the N-terminal EC domain structure but lacking transmembrane and 
cytoplasmic domains (Fig. 1).  
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Figure 1: Schematic overview of the cadherin superfamily (5). 
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E-cadherin was the very first cadherin to be discovered; it was found in the early 1980s by Jacob 
and coworkers and was then named uvomorulin (6, 7). Soon afterwards N-cadherin was found in 
neural tissue (8, 9) and P-cadherin was found in placental tissue (10). Now, almost three decades 
on, more than 100 cadherins have been reported (11). Molecular phylogenetic analysis of cadherin 
family revealed six major subfamilies in addition to several solitary members (11). The six 
subfamiles comprise classical or type I cadherins, atypical or type II cadherins, desmocollins, 
desmogleins, protocadherins and flamingo cadherins; solitary members include T-cadherin, FAT 
and many invertebrate cadherins (Fig. 2). 
 
 
 
 
 
Figure 2: Phylogenetic tree of the cadherin superfamily (11). 
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Classical cadherins 
 
Classical cadherins were the first cadherin subtype identified. They are expressed by almost all 
vertebrate tissues, are responsible for homophilic adhesion and are localized within adherent 
junctions. Classical cadherins have five EC domains and modulate adhesion through dynamic 
interactions with the cytoskeleton. The cytoplasmic domain of classical cadherins contains highly 
conserved unique sequences. Classical cadherins can be subdivided into type I and type II according 
to the presence or absence of a Histidine-Alanine-Valine (HAV) motif on the first extracellular 
domain (EC1) which is the domain responsible for homophilic adhesion. Type I classical cadherins 
possess this HAV motif; E-cadherin, N-cadherin, P-cadherin, M-cadherin and EP-cadherin belong 
to this family. Type II cadherins do not possess the HAV motif but contain conserved tryptophan 
residues in EC1; VE-cadherin, Cadherin-11, Cadherin-8 and MN-cadherin belong to this family 
(12). Type II classical cadherins have been reported to exhibit heterophilic adhesion (13). 
Additionally it is recognized that EC domains of some cadherins (e.g. N-cadherin) can bind to other 
proteins such as fibroblast growth factor to induce downstream signaling (14). 
 
Conserved cytosolic domains of classical cadherins interact with either β− or γ− catenin which bind 
to α-catenin, which in turn interacts with the actin cytoskeleton via vinculin (Fig. 3) (5). Cadherin 
binding to β-catenin and the involvement of the latter in the Wnt  
 
 
 
Type I Classical 
cadherins 
 
 
 
 
 
 
Type II Classical 
cadherin 
 
 
Figure 3. Homophilic adhesion between classical cadherins (5). 
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signaling pathway enables cross-talk between cadherins and the Wnt pathway leading to modulation 
of several biological activities such as proliferation, migration and cell survival (15, 16). The 
cytoplasmic domain of classical cadherins also has binding affinities for various other proteins 
responsible for modulation for interactions with actin, thereby affecting the strength of homophilic 
adhesion. These include small GTPases CDC42 and Rac and IQGAP1 (17-19). IQGAP1 also binds 
to calmodulin which plays a role in modulating calcium sensitive environment for the homophilic 
adhesion of cadherins (20). p120, an armadillo family protein has been demonstrated to regulate 
CDC42 and Rac in cadherin interactions (21). 
 
Type II classical VE-cadherin, specific to vascular endothelial cells, has multiple cytoplasmic 
binding partners (Fig. 3). In addition to p120 regulated binding with α/β and γ-catenin to actin, the 
cytosolic domain of VE-cadherin binds to plakoglobin (PG) which in turn binds to desmoplakin 
(DP) and then to Intermediate Filaments (IF) (22), (23).  
 
Classical cadherins play a pivotal role in tissue morphogenesis during development. Different roles 
of cadherin during development are illustrated in Fig. 4. 
 
 
Figure 4: Developmental roles of cadherins (1). 
 
Each subtype of cadherin tends to exhibit restricted and distinct cell type expression. E-cadherin is 
expressed in epithelium, N-cadherin in neural tissue and muscle, R-cadherin in forebrain, P-
cadherin in placental tissue, Cadherin-6 in kidney and VE-cadherin in endothelium. Tight regulation 
in expression of various cadherins during different stages of development is accomplished by a 
prominent phenomenon known as “Cadherin switching”. A classical example of cadherin switching 
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is Epithelial-to-Mesenchymal Transition (EMT) during mesoderm formation in embryogenesis. 
During EMT, epithelial cells transit from an epithelial morphology with a stationary phenotype to a 
mesenchymal and fibroblastic morphology with a migratory phenotype through a concomitant loss 
of E-cadherin expression and gain of N-cadherin expression. The phenomenon of EMT has been 
well studied in the context of tumor progression and metastasis.  
 
VE cadherin belonging to the Type II classical subtype is expressed only in the endothelium and 
plays a crucial role in vasculogenesis, vascular permeability and vascular remodeling. The 
cytoplasmic tail of VE-cadherin complexes with VEGF receptor and induces PI3K/Akt pathway 
signaling resulting in positive effects on endothelial cell survival, proliferation and migration.(24).  
 
Protocadherins 
 
The protocadherin subfamily comprises more than 80 members, representing the largest group of 
the cadherin superfamily. Protocadherins are expressed by all vertebrates and certain sea sponges. 
Protocadherins possess 4-7 EC domains and although they have calcium-dependent homophilic 
interaction activity, the activities are relatively weak compared with the classical cadherins. (25, 
26). Further unlike classical cadherins, the cytoplasmic domains of protocadherins are highly 
variable, and most of them do not show any appreciable homology with the cytoplasmic domains of 
classic cadherins. Some protocadherins have heterophilic interaction activity and their cytoplasmic 
domains associate with unique cytoplasmic proteins, which confer various biological functions on 
the protocadherins (26).It has been proposed that the main function of protocadherins may not be 
the cell– cell adhesion activity, but other functions such as the specificity determination of cell– cell 
interaction and signal transduction (26).  
 
Interactions between the cytoplasmic domain of protocadherins and intracellular proteins remain 
poorly investigated. Two of the better studied protocadherins are μ-cadherin which can bind via its 
PDZ domain, and CNR-cadherin which is localized in rafts which can interact with src family 
kinase FYN. In mammals protocadherins are expressed in the nervous system and an important 
function appears to involve synapses (27). The role of protocadherins in development has been well 
studied in xenopus and zebrafish. Paraxial protocadherin (PAPC) and axial protocadherin (APC) are 
very important in regulation of embryogenesis. ARCADLIN is induced by synaptic activity (28). 
Recently epigenetic methylation of Protocadherin 10 was observed in hematologic malignancies 
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(29). In humans protocadherins are regulated by a large gene cluster located in 5q31-33; 
interestingly, genomic sequences corresponding to the ECs of many protocadherins have essentially 
no introns, (30), which is in a sharp contrast to the case of classic cadherins. 
 
Desmosomal Cadherins 
 
Desmosomal cadherins are located at desmosomes, which are sites for cell-cell adhesion present in 
tissues subjected to mechanical strain such as epidermis and myocardium. Desmosomal cadherins 
comprise two subfamilies, desmocollin (DSC) and desmoglein (DSG), each possessing three 
subtypes, DSC 1, DSC2, DSC 3 and DSG 1, DSG 2, DSG 3 (31). EC domains of desmosomal 
cadherins possess 50% homology with classical cadherins. (11). Cytoplasmic domains of DSC and 
DSG interact with intermediate filaments bound to plakoglobin and plakophilins via desmoplakins 
(Fig. 5).  
 
Figure 5: Desmosomal cadherins (11). 
 
DSC 1 is expressed in differentiated uppermost epithelium and papillae of tongue. DSC 2 is widely 
expressed in epithelia, lymph nodes and cardiac muscle. DSC 3 is expressed in epithelia. DSG 1 
and 3 are confined to stratified squamous epithelium and DSG 2 is expressed by all the tissues 
possessing desmosomes. (11). RNAi mediated silencing of DSC 2, expression of dominant negative 
DSG and knockout DSG 3 results in decline in desmosomes, increased asymmetry and detachment 
of desmosomes (32, 33). Desmosomes are often observed in heterophilic adhesion (34). Gene 
clusters of desmosomal cadherins are located on 18q12 where they are arranged in a DSC cluster 
and a DSG cluster.  
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Solitary members of cadherin superfamily 
 
The FAT family members 
Drosophila FAT is a very large cadherin protein with 34 tandem EC domains, four EGF repeats, 
two laminin repeats, a single transmembrane-spanning region and a cytosolic domain. Recessive 
lethal mutations in FAT leads to defects in larval imaginal disc overgrowth and differentiation (35). 
Drosophila daschsous protein is highly related to FAT and has 27 EC domains. Daschsous is 
expressed in imaginal discs and brain in larvae. FAT and daschsous have cytoplasmic domains 
predicted to bind β-catenin. (36). Recently it was reported that human FAT1 is involved in vascular 
smooth muscle cell proliferation and migration (37). 
 
Seven transmembrane cadherins 
Seven transmembrane cadherins, also known as starry night or Flamingo (Fmi), were first identified 
in drosophila. These posses 9 EC domains, EGF like domains and a laminin motif in addition to a 
seven transmembrane-spanning domain homologous to GPCRs and a cytosolic domain (38). 
Cytoplasmic tails do not contain any catenin binding domain and putative binding partners have not 
yet been identified. Fmi exhibits homophilic and homotypic adhesion properties Two mammalian 
paralogues have been identified, mCELSRI in mouse (39) and hMEGF2 in humans (40). Mutations 
in Fmi have recently been shown to lead to retinal axon malfunction (41). 
 
T-cadherin 
T-cadherin (T-cad) is unusual member of cadherin superfamily; while possessing the N-terminal 
tandem cadherin repeat structure, its lacks both transmembrane and cytoplasmic domains, and is 
bound to the plasma membrane via a glycosylphosphatidylinositol (GPI) anchor (42). T-cad was 
first cloned from cDNA pool of chick embryo brain (42). The most N-terminal EC domain has 58% 
homology with E-cadherin but does not posses the HAV motif that is crucial to homophilic 
interactions mediated by the classical cadherins (11). T-cad has five EC domains and a propeptide 
in its precursor form (130kDa), which upon cleavage gets converted to mature form (105kDa) (Fig. 
6); unlike the classical cadherins, the precursor form of T-cad is also expressed on the cell surface.  
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extracellular  
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glycosylphosphatidylinositol (GPI) anchor propeptide 
 
 
Figure 6: Schematic diagram of T-cadherin structure. 
 
CHO cells upon transfection with T-cad cDNA exhibit only weak calcium-dependent homophilic 
adhesion. Adhesive properties of T-cad in transfected cells were abrogated when treated with 
phosphatidylinositol-specific phospholipase C, suggesting some involvement of the GPI anchor 
(43). However, accumulating data suggests that T-cad shares little functional similarity with 
classical members of the cadherin family. In particular, the global distribution of T-cad over the cell 
body, its absence at intercellular contacts in cell monolayers, and its localization to the apical 
surface of polarized transfected cells imply that participation in the formation of intercellular 
adherent junctions is not a major function of T-cad. 
 
A role for T-cad in tissue organization was first demonstrated in the avian embryonic nervous 
system where the protein influenced the pattern of neural crest cell migration and maintained somite 
polarity (44). T-cad inhibited neurite outgrowth when neuron populations were grown on T-cad 
substrata and anti T-cad antibodies abrogated the effects, suggesting T-cad acts as negative 
guidance cue for axon projections (45). T-cad is also expressed in human brain where it acts as 
negative growth regulator of epidermal growth factor in neuroblastoma cells (46).  
 
T-cad gene is localized on 16q24 and has been described as tumor suppressor gene since many 
cancer cell lines (e.g. breast, colon, lung, inter alia) display allelic loss of T-cad which is correlated 
with tumor progression (47). Frequent epigenetic modification of T-cad promoter by aberrant 
methylation resulting in allelic loss and diminished expression of T-cad has been reported for a 
variety of cancers including breast (48), lung (49, 50), colorectal (51) (52), cervical (53), and 
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nasopharyngeal (54), digestive tract (55, 56), skin (57, 58), pancreatic (59) cancers and also chronic 
myeloid leukemia (60) and malignant B cell lymphomas (61). In PC12 cells T-cad has been 
demonstrated to be a target gene for DNA methytransferase 3B (Dnmt3b), but Dnmt3b-dependent 
suppression of T-cad expression occurs via methylation-independent mechanisms (62). T-cad has 
been shown to be regulated by glucocortocoids and aryl hydrocarbon agonists in osteocarcinoma 
cell lines and vascular smooth muscle cells, respectively (63, 64).  
 
Investigations on T-cad in the cardiovascular system, where T-cad is highly expressed, suggest 
biological functions that are distinct from the tumor suppressive role described in the field of 
oncology, but which rather bear resemblance to the negative guidance role described in the 
embryonic nervous system. Current knowledge about the role of T-cad in the vasculature is 
discussed in detail in section 1.3. 
 
1.2 Vascular remodeling 
 
Normal vasculature: structure and function 
The normal muscular artery comprises three layers (Fig. 7). The adventitia, the outermost layer, 
consists of fibroblasts, collagen, proteoglycans and vasa vasorum. The media comprises smooth 
muscle cells (SMC) and collagen fibers. Media and adventitia are separated by the external elastic 
lamina. The intima is composed of endothelial cells (EC) and underlying connective tissue. Intima 
and media are separated by the internal elastic lamina. 
 
 
Figure 7: Schematic structure of normal large artery (65). 
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The vascular endothelium forms a continuous monolayer lining blood vessels and heart. In adult 
human the endothelium covers a surface of 1000m2, displaying a cobble stone morphology with 
polygonal and tightly bound EC (66, 67). Functions of EC are heterogeneous in different vascular 
bed due to differential gene expression and the influence of surrounding tissues (68). EC regulate 
many biological processes:(1) serve as a semi-permeable membrane, controlling transfer of 
molecules into the vessel wall; (2) maintain a non-thrombogeneic blood-tissue interface by 
regulating thrombosis, thrombolysis and platelet adherence; (3) modulate vascular tone and blood 
flow; (4) regulate immune inflammatory reactions, largely controlling leukocyte interactions with 
vessel wall; (5) modify lipoproteins in artery walls;  (6) regulate growth of other cell types, 
particularly SMC. 
 
SMC are spindle shaped with single elongated nuclei. SMCs perform many important functions; (1) 
vasoconstriction and dilation in response to physiological and pharmacological stimuli by 
contraction and relaxation, thereby controlling blood pressure; (2) synthesis and deposition of 
collagen, elsatin and proteoglycan; (3) synthesis and secretion of growth factors, cytokines; (4) 
migration and proliferation during vessel repair and remodeling.  
 
Vascular remodeling in proliferative vascular disorders (atherosclerosis, restenosis) 
Vascular remodeling is essentially a process of redistribution of the cellular constituents of vessel 
wall resulting in change of their structure and function without changing volume. Vascular 
remodeling is a physiologically protective phenomenon during embryogenesis, wound healing and 
the reproductive cycle. Pathological vascular remodeling leads to various vascular disorders such as 
hypertension, atherosclerosis and restenosis after vessel injury, resulting in enhanced 
vasoconstriction and reduced blood flow. Clinical complications resulting from pathological 
remodeling include myocardial infarction and stroke.  
 
Abnormal endothelial activation such as bacterial infection or inflammation leads to local 
alterations in the endothelium affecting homeostasis, control of vascular tone and increased 
permeability. Such malfunctions of the endothelium are collectively referred to as endothelial 
dysfunction (69). A dysfunctional endothelium is more permeable to cholesterol containing low 
density lipoprotein which increasingly accumulate within the intima, undergo oxidation and 
promote atherosclerosis. Activated EC express intercellular adhesion molecule (ICAM), vascular 
adhesion molecule (VCAM), platelet- endothelial cell adhesion molecule (PECAM), selectin and 
integrins for recruitment of monocytes (70), followed by their transendothelial migration into 
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intima. Within the intima monocytes differentiate into macrophages in response to macrophage 
colony-stimulating factor and produce reactive oxygen species which oxidize LDL (65). Oxidized 
LDL is engulfed by macrophages which become foam cells. T-cells (usually CD4+), mast cells, 
dendritic cells, B-cells and NKT cells are different immunocompetent cells that can migrate into the 
intima and produce cytokines like interleukins (IL-4, IL-13, IL-5, IL-10, IL-8), TGFβ, ΙFN-γ and 
TNFα. The cytokine-rich extracellular milieu sustains a proinflammatory status and SMC 
proliferation and migration to the intima (intimal thickening), and also induces neovessel formation 
(neovascularization); the combination of these processes increases the mechanical vulnerability of 
the atherosclerotic plaque and the risk of plaque rupture and thrombosis (71, 72). A schematic 
representation of cellular composition of atherosclerotic plaque is shown in figure 8. 
 
 
Figure 8: Cellular composition of atherosclerosis plaque(71). 
 
Intimal thickening: Proliferation and migration of SMC from media to intima plays a key role in 
neointima formation and thickening. Followed by intimal injury, different cell types including EC, 
platelets and inflammatory cells release growth factors and cytokines which results in phenotypic 
change of SMC from contractile quiescent state to active synthetic state leading to SMC 
proliferation (65, 73). Platelet derived growth factor (PDGF), basic fibroblast growth factor (bFGF), 
transforming growth factor β1 (TGF β) epidermal growth factor (EGF) and insulin growth factor 
(IGF) are major growth factors affecting SMC proliferation and migration (74). SMC migration and 
proliferation is also modulated by extracellular matrix (ECM) components such as integrins, 
collagen, fibronectin, thrombospondin, tenascin and vitronectin (75), and by metalloproteinases and 
cadherins (76). 
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Neovascularization: Vasa vasorum normally nurture the outer (adventitial) layer of the vessel wall. 
Neovascularization  frequently accompanies pathological thickening of the intima; there is an 
increase in vasa vasorum which become a major source for nutrients to the thickened vessel wall 
(77). EC proliferation, migration and outgrowth are key cellular events for neovascularization 
within plaque. Intimal thickening creates conditions of hypoxia whereby hypoxia inducible factor 
(HIF-1) is released with subsequent induction of proangiogeneic molecules such as vascular 
endothelial growth factor (VEGF), VEGF receptors, endothelial nitric oxide synthase (eNOS) and 
ephrins (78). Intra-plaque neovascularization facilitates RBC extravasation, lipid deposition and 
cause internal bleeding resulting in plaque instability (77).  
 
Oxidative stress in cardiovascular disorders 
Oxidative stress is a common risk factor in many cardiovascular diseases and plays a pivotal role in 
each step of pathophysiology of atherosclerosis and other cardiovascular disorders. Important 
sources of reactive oxygen species (ROS) are NADPH oxidases, Xanthine oxidase and eNOS (79). 
ROS produced from vascular cells oxidizes LDL leading to stimulation of macrophages and other 
inflammatory cells (72). Cytokines, TNF-a, angiotensin II and VEGF induce adhesion molecules 
such as VCAM-1, ICAM-1 and P-selectin in a ROS dependent fashion (80). As mentioned above 
SMC proliferation and migration are key processes in neointima formation; induction of SMC 
proliferation and migration by PDGF requires endogenously produced H2O2 (81). 
Metalloproteinases facilitating degradation and reorganization of extracellular matrix during 
vascular remodeling are activated by ROS (82). Significant induction of NADPH oxidase 
dependent ROS is observed in experimental restenosis (rat carotid artery balloon injury) (83). 
Oxidative stress is also reported to induce intraplaque angiogenesis in experimental models leading 
to plaque destabilization (84). Various roles of oxidative stress in cardiovascular disorders have 
been extensively reviewed (85-88). 
 
1.3 T-cadherin in the vasculature 
 
T-cadherin is widely expressed in the vasculature. EC and SMC, resident cells of the vessel wall 
express both precursor (130kDa) and mature (105kDa) forms of T-cad. Initially T-cad was 
identified in human aortic media membranes isolates as an atypical low density lipoprotein (LDL) 
binding protein of 105kDa (called p105) using ligand (LDL) binding techniques (89). Partial 
sequencing of this p105 revealed its identity as T-cad (90). Subsequent ligand binding studies 
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demonstrated the co-existence of the 130kDa precursor form of T-cad in membranes of SMC and 
its ability to bind LDL (91). A 100-fold molar excess of HDL was required to abrogate 50% of the 
LDL-binding activity of T-cad, suggesting lipoprotein-specificity of this activity (89). GPI-specific 
phospholipase C treatment of SMC and conditions of calcium-depletion inhibited the LDL-binding 
activity of T-cad (91). HEK293 cells transfected with T-cad exhibited increased cell aggregation 
and LDL binding activity in a both calcium- and GPI-dependent- fashion (92). LDL-binding to T-
cad was not detected when electrophoresis was conducted under reducing conditions suggesting a 
requirement for intact disulfide linkages (89). GPI-less T-cad transfected in HEK293 cells and E. 
coli did not exhibit LDL binding indicating a requirement of the GPI moiety; other GPI-anchored 
proteins did not show any affinity towards LDL (92). Another group later demonstrated that in 
HEK293 cells transfected with T-cad LDL-binding induced elevation of intracellular calcium levels 
and increased cell migration (93).  
 
Although T-cad is expressed in various organs and tissues, Western blotting (Fig. 7) revealed its 
predominant expression in cardiovascular tissues (heart, aorta, carotid, iliac and renal arteries, with 
the highest level in the aorta) (94). In the nervous system T-cad protein was shown to be expressed 
in spinal cord, but not in the cerebral cortex, cerebellum and hypothalamus. However, Northern 
analysis revealed the presence of T-cad mRNA in cerebral cortex, thalamus and midbrain (46). T-
cad is not expressed at detectable levels in secretory organs (liver, pancreas, thyroid and adrenals), 
hollow organs (stomach, esophagus, intestine, and bladder) and pulmonary tissues (Fig. 7). In vitro 
cultures of epithelial cells, neuronal cells and fibroblast cells do express T-cad.  
Figure 7: Expression of T-cad in human tissues/organs (94). 
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Immunohistochemical analysis of aorta sections revealed expression of T-cad in EC, SMC and 
pericytes but not in adventitial fibroblasts or in blood derived cells (Fig. 8A & B). The highest 
expression of T-cad was observed in intima and in its proteoglycan layer.  
 
Non-immuneAnti-T-cad
Anti-T-cad + Anti-SMC α−actin
Figure 8: T-cad in human aorta sections (94). 
 
T-cad was colocalised with smooth muscle α−actin and an inverse relationship between intensities 
of their expression was observed (94). Cells located to the subendothelial intimal layer expressed 
low levels of smooth muscle α−actin and high levels of T-cad. In contrast, cells in the deeper 
muscular-elastic intimal layer displayed high levels of smooth muscle α−actin and low levels of T-
cad, suggesting a phenotype-associated expression of T-cad expression (Fig. 8 D&E). Although T-
cad was not present in the adventitial layer, T-cad was highly expressed in adventitial vasa vasorum 
(composed of EC). 
 
Immunohistochemical analysis of atherosclerotic lesions of varying severity indicated upregulation 
of T-cad in intimal SMC as compared to normal aortal tissue (94). Experimental restenosis 
following balloon catheterization of the rat carotid artery was associated with elevation of T-cad 
expression at an early time after endothelial injury, and with a further elevation during the 
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subsequent phase of neoinitmal formation that is characterized by increased SMC cell migration 
and proliferation (95). Taken together the data suggested that upregulation of T-cad during 
atherosclerosis and experimental restenosis might play some role in vascular remodeling. 
 
GPI-anchored T-cad is not localized at adherent junctions but rather distributed globally over the 
cell surface. T-cad is localized within lipid rafts; these are cholesterol- and sphingolipid-rich 
membrane domains which are enriched with other GPI-anchored proteins (e.g. CD59 and uPA 
receptor) and signaling molecules (e.g. Src kinases) (96). This raft domain location of T-cad 
together with the outward orientation of T-cad implies some sensory function and participation in 
signal transduction.  
 
In vitro data supports participation of T-cad in many cellular processes such as vascular 
differentiation, migration and proliferation of SMC and EC and angiogenesis. Adenoviral mediated 
overexpression of T-cad in EC and SMC resulted in cell cycle progression and a concomitant 
promotion of proliferation (97). T-cad exhibits deadhesive functions upon homophilic ligation with 
antibody against T-cad or with recombinant immobilized soluble protein (98). Homophilic ligation 
of T-cad induces polarization and migration of endothelial cells in a RhoA/ROCK and Rac 
dependent fashion (99, 100). T-cad stimulates in-gel outgrowth of endothelial sprouts in 3-
dimensional EC-spheroid and heart tissue models of angiogenesis. In vivo, myoblast-mediated 
delivery of recombinant soluble T-cad to mouse skeletal muscle facilitates VEGF-induced 
angiogenesis, supporting a physiological role for T-cad as a proangiogenic protein (101). 
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2. Dissertation objectives 
 
In spite of major progress toward understanding the function of T-cad in vascular cells, knowledge 
regarding the regulation of T-cad expression and the signaling mechanisms whereby T-cad affects 
vascular cell behaviour is limited. This thesis focuses on three issues. 
 
T-cad and oxidative stress (section 3.1.):  
In vascular tissue, T-cad is up-regulated in vivo under disease conditions associated with oxidative 
stress and concomitant cell migration, proliferation and apoptosis/survival. It is possible to 
hypothesize some functional relationship between oxidative stress, T-cad expression, and cell 
survival status. The specific objectives here were: 
1) To investigate whether T-cad is modulated in EC by oxidative stress  
2) To investigate whether T-cad plays a role in regulating apoptosis/cell survival of EC  
3) To identify intracellular signaling pathways activated by T-cad in EC  
 
T-cad and molecular mediators (section 3.2.):  
T-cad influences several parameters of angiogenesis including endothelial cell (EC) differentiation, 
migration, proliferation and survival. This presupposes signal transduction networking via 
mediatory regulators and molecular adaptors since T-cad lacks transmembrane and cytosolic 
domains.The specific objectives here were: 
1) to identify a membrane proximal molecule that could mediate inward signal transmission by 
GPI-anchored T-cad. 
2) to further delineate proliferation and survival signal transduction mechanisms activated by 
T-cad in EC 
 
Transcriptional regulation of T-cad (section 3.3): 
T-cad has been referred to as a tumor suppressor gene since T-cad expression is diminished by 
aberrant promoter methylation in malignant cells. The transcriptional regulation of T-cad in 
vascular cells has not been studied. The specific objectives here were: 
1) to characterize the minimal promoter region of T-cad 
2) to study the transcriptional regulation of T-cad in EC  
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3. Methods and Results 
 
3.1. T-cad and oxidative stress 
 
The results of this project have been published. 
T-cadherin protects endothelial cells from oxidative stress-induced 
apoptosis. 
FASEB J. 2005 Oct;19(12):1737-9.  
 
(The paper is appended) 
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ABSTRACT 
In vascular tissue, T-cadherin (T-cad) is up-regulated in vivo under disease conditions associated 
with oxidative stress and concomitant cell migration, proliferation and apoptosis/survival. Using 
cultures of human umbilical vein endothelial cells (HUVEC), we examined whether there is a 
functional relationship between oxidative stress, T-cad expression, and cell survival status. 
Culture of HUVEC under conditions of oxidative stress (e.g., serum deprivation, inclusion of 
H2O2) resulted in increased T-cad expression. Oxidative stress-induced increases in T-cad were 
inhibited by the free radical-scavenging antioxidant, N-acetylcysteine, and the flavin-containing 
oxidase inhibitor, diphenyleneiodonium. Thus reactive oxygen species (ROS) contribute to 
stress-induced elevation of T-cad in HUVEC. Compared with control cells, HUVEC 
overexpressing T-cad (T-cad+-HUVEC) had higher phosphorylation levels for 
phosphatidylinositol 3-kinase (PI3K) target Akt and mTOR target p70S6K (survival pathway 
regulators), but lower levels for p38MAPK (death pathway regulator). T-cad+-HUVEC exposed 
to stress (serum-deprivation, TNF-α, actinomycin D, staurosporine) exhibited reduced caspase 
activation together with increased cell survival. Protection against stress-induced apoptosis in T-
cad+-HUVEC was abrogated by either PI3K-inhibitor wortmannin or mTOR-inhibitor 
rapamycin. We conclude that T-cad overexpression in HUVEC protects against stress-induced 
apoptosis through activation of the PI3K/Akt/mTOR survival signal pathway and concomitant 
suppression of the p38 MAPK proapoptotic pathway. ROS-induced changes in T-cad expression 
may play an important role in controlling tissue cellularity during vascular remodeling. 
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-cadherin (T-cad, H-cadherin, cadherin-13) is an atypical glycosylphosphatidylinositol 
(GPI)-anchored member of the cadherin superfamily (1). In contrast to classical cadherin 
family members, T-cad lacks the typical transmembrane and cytoplasmic domains, is 
globally distributed over the cell body, is absent at intercellular contacts in cell monolayers, and 
undergoes redistribution to the leading edge in migrating vascular cells (2). T-cad can mediate 
calcium-dependent, homophilic binding in transfected cells, but these interactions are weak 
because absence of linkage to the cytoskeleton does not permit the formation of stable 
T 
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 intercellular adhesive forces (1, 3). Moreover, in polarized transfected cells T-cad is localized to 
the apical but not the baso-lateral surface (4). Thus T-cad is functionally distinct from classical 
cadherins with respect to formation of intercellular adherent junctions. 
Accumulating data indicate that T-cad may have multiple signaling functions in vascular 
remodeling processes. In vascular tissue, T-cad is up-regulated during atherosclerosis (5), 
restenosis after balloon angioplasty (6), and tumor angiogenesis (7), these being conditions 
associated with migration and proliferation, as well as concomitant apoptosis of resident smooth 
muscle cells (SMC) and endothelial cells (EC) (8–11). T-cad has been attributed to function as a 
guidance receptor, which would be relevant to migratory processes. Homophilic ligation of T-
cad has been shown to function as a repulsive cue for motor-axon projection in the embryonic 
nervous system (12), to promote deadhesion in SMC and EC (13), and also to induce 
RhoA/ROCK- and Rac-dependent cell polarization and directed cell migration in EC (14). A 
positive functional relationship between levels of T-cad expression and proliferation in vascular 
cells also exists, although this does not depend upon homophilic ligation. T-cad levels were 
higher in sparsely seeded, exponentially growing cultures of SMC than at confluency (15); cell 
cycle analysis in SMC and EC cultures demonstrated higher expression of T-cad in S-and G2/M-
phases than in G1/G0-phase (16), and overexpression of T-cad in EC or SMC facilitated cell 
cycle progression and proliferation (16). Paradoxically, up-regulation of T-cad was observed in 
rat aortic SMC cultured after serum starvation for a prolonged (48 h) period (15). Withdrawal of 
growth factors and nutrients from cultures of normally adherent cells can lead to weakened 
extracellular matrix attachment and induction of apoptosis (17, 18). However, given the positive 
relationship between T-cadherin expression and proliferation of vascular cells in vivo (5–7) and 
in vitro (16), up-regulation of T-cad may rather participate in cell survival responses to stress. 
Here, we address mechanisms underlying the elevation of T-cad in serum-starved EC and the 
influence of elevated T-cad on EC survival status. In vitro, serum withdrawal is known to induce 
oxidative stress through excess production of reactive oxygen species (ROS) (19–21), and 
disruption of cell attachment to extracellular matrix leading to cell detachment is also associated 
with an elevation of ROS (17, 22). ROS are also elevated in vivo during atherosclerosis, 
restenosis, and angiogenesis and play a major role in control of tissue cellularity through 
signaling effects on diverse biological processes, including both survival and apoptosis (11, 23–
26). The ultimate survival or death response to a given condition of oxidative stress reflects the 
balance between signaling pathways that are directly or indirectly modulated by ROS. Vascular 
cells possess a multitude of redox-sensitive signaling systems, including, inter alia, the 
extracellular signal–regulated kinases (ERKs), the stress-activated protein kinase (SAPK) family, 
which include c-Jun N-terminal kinases (JNKs) and p38 MAPK, Akt, and caspases (11, 23–27). 
In this study, we investigated whether oxidative stress up-regulates T-cadherin expression in EC. 
The functional role of the increase in T-cadherin expression in endothelial cell survival and the 
underlying signaling pathways were analyzed. 
MATERIALS AND METHODS 
Cell culture 
Human umbilical vein endothelial cells (HUVEC) were purchased from PromoCell GmbH 
(Heidelberg, Germany) and normally cultured in basal endothelial cell growth medium 
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 containing low serum (2% FCS) and endothelial cell growth supplement (PromoCell). All tissue 
culture surfaces were precoated with 0.1% gelatin, and HUVEC were used at passages 2-6, 
during which expression of markers (von Willebrand factor, CD 31, VE-cadherin) for 
differentiated EC remained steady. Some experiments were repeated using the immortalized 
human microvascular EC line HMEC-1 (28), for which culture conditions were as above but 
with FCS at 10%. Apoptosis was induced by inclusion of TNF-α (40 ng/ml), staurosporine (1 
μM), actinomycin D (100 ng/ml), high glucose (30 mM) or serum withdrawal (DMEM/0.1% 
BSA). For analysis of the involvement of ROS, the following compounds were used; H2O2 (1 
mM), for generation of ROS, N-acetylcysteine (NAC; 30 mM), a ROS scavenger, 
diphenyleneiodonium (DPI; 10 μM), an inhibitor of flavin-containing oxidases, mitochondrial 
(complex I) NADH dehydrogenase inhibitor (rotenone; 10 μM), and inhibitor of the 
mitochondrial (complex III) cytochrome b-c1 inhibitor (antimycin A; 10 μM), and nitric oxide 
synthase (NOS) inhibitor N-monomethyl-L-arginine (L-NAME; 1 mM). Wortmannin (10 nM) 
and rapamycin (10 nM) were used to inhibit PI3 kinase (PI3K) and phosphorylation of p70 S6 
kinase (p70S6K), respectively. HA14-1 (50 μM) was used to inhibit Bcl-2. The above chemical 
compounds were purchased from Sigma-Aldrich Chemie (Deisenhofen, Germany). Experimental 
protocols variously applied in this study are described within the Results and figure legends. 
Fluorescence microscopy 
HUVEC were plated (3×104 cells/well) into 8-well chamber Lab-Tek Permanox slides precoated 
with 0.1% gelatin, cultured overnight, and then subjected to serum deprivation until the cells 
began to detach (4–6 h). HUVEC were fixed with 4% paraformaldehyde in PBS, preincubated 
with 10% FCS in PBS and then immunostained for T-cad using purified polyclonal antibody 
against the first extracellular domain of T-cad (or nonimmune rabbit IgG for controls) and 
secondary Cy3-labeled anti-rabbit antibodies (Jackson ImmunoResearch Laboratories, West 
Grove, PA) (2, 13). Nuclei were counterstained with Hoechst (Molecular Probes, Leiden, 
Netherlands). All procedures were carried out at room temperature and with careful rinsings in 
order to avoid loss of all weakly adherent cells. Images were captured using an Olympus IX-50 
inverted microscope equipped with a digital camera (Olympus Optical, Schwerzenbach, 
Switzerland) and AnalySIS 3.2 software (Soft Imaging System GmbH, Münster, Germany). 
Adenoviral infection 
Overexpression of T-cad in HUVEC using Adeno-X Expression System (Clontech, Palo Alto, 
USA), determination of viral titers and infection protocols have been detailed previously (13, 
16). Briefly, HUVEC in normal growth media were seeded at a density of 1-2 × 104cells/cm2, 
allowed to adhere and infected overnight with empty- or T-cad-containing adenoviral particles at 
a final approximate concentration of 100 pfu/cell. Uninfected parental HUVEC and empty-
vector- or T-cad-containing vector infected cells adhere identically onto the standard gelatin-
coated substratum (13). 
Immunoblotting 
The method of immunoblotting has been described previously (15). Lysis buffer was normally 
PBS containing 1% SDS and protease inhibitor cocktail (Sigma), with inclusion of 1 mM 
orthovanadate and 5 mM NaFl in samples analyzed for protein phosphorylation status, protein 
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 concentrations were determined using the Lowry method, and electrophoresis was in 8% or 10% 
SDS-polyacrylamide gels under reducing conditions. Protein loading equivalence was routinely 
controlled after electrotransfer to nitrocellulose membranes by staining with Ponceau S and by 
immunoblotting for Gαs subunit. The following primary antibodies were used: rabbit antibody 
against the first extracellular domain of T-cad generated in our lab (5); anti-Gαs (Calbiochem, 
Darmstadt, Germany); anti-cleaved caspase-3 (Asp175), Akt, phospho-(Ser473)Akt, Fak, phospho-
(Tyr576/577)Fak, ERK1/2, phospho-(Thr202/Tyr204)ERK1/2, p38, phospho-(Thr180/Tyr182)p38, 
JNK1, phospho-(Thr183/Tyr185)JNK1, p70S6K and phospho-(Thr389)p70S6K, BCL-XL, p21 (all 
from Cell Signaling, New England Biolabs GmbH, Frankfurt, Germany), survivin (Abcam, 
Cambridgeshire, UK). For negative controls, nonimmune rabbit or mouse IgG (Sigma-Aldrich 
Chemie, Deisenhofen, Germany) were appropriately used as the substitute for primary antibody. 
Secondary HRP-conjugated anti-rabbit IgG (1:5000) and HRP-conjugated anti-mouse IgG 
(1:5000) were from Southern Biotechnology (BioReba AG, Reinach, Switzerland). Amersham 
ECL (Amersham Biosciences, Little Chalfont, UK) and the Enhanced Luminescence System or 
SuperSignal West Dura from Pierce (Rockford, IL) were variously used for detection of 
immunoreactive proteins. Scanned images of Ponceau S stains and immunoblots were analyzed 
using AIDA Image or Scion (NIH) Image software. Figures show representative immunoblots. 
Assay for caspase activity 
HUVEC were seeded at 2 × 104 cells/well in 96-well plates and allowed to adhere overnight. 
After apoptosis induction protocols as described in the Results, cells were assayed for caspases 
activity fluorimetrically (λex=499 and λem=520) using a fluorimetric caspase assay kit 
(Homogeneous caspases assay as per manufacturer’s instructions; Roche Diagnostics GmbH, 
Mannheim, Germany). Substrate solution was added to wells without prior removal of any 
detached cells or medium change. Unless otherwise specified, caspase activity is expressed as 
arbitrary fluorescence units (au.) per 2 × 104 cells. 
Assay for cell survival 
For these assays, HUVEC were seeded at 1.5 × 105 cells/well in 6-well plates and allowed to 
adhere overnight before experimentation. To estimate cell survival following treatments, 
detached cells were removed by medium aspiration, wells were rinsed with PBS and numbers of 
remaining adherent cells quantitated by enzymatic detachment (0.25% trypsin/1mM EDTA in 
PBS) and counting in a Coulter counter. Cell survival (presented in figures as % of serum 
control), expresses the number of adherent cells present after a given treatment relative to those 
in untreated controls (arbitrarily taken as 100%). 
Statistics 
Unless otherwise stated all results are given as means ± SD, and at least 3 independent 
experiments for any given protocol were performed. Statistical analyses were performed by one-
way ANOVA followed by post hoc Bonferroni’s multiple comparison test when appropriate. A P 
value of <0.05 was considered significant. 
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 RESULTS 
T-cad is up-regulated in apoptotic cells 
The first series of experiments were designed to generally assess whether there might be some 
relationship between T-cad expression on endothelial cells and apoptosis. HUVEC were cultured 
under a variety of conditions known to induce apoptosis; these included culture under normal 
serum-containing conditions with inclusion of high glucose (30 mM) for 72 h, inclusion of TNF-
α (40 ng/ml), staurosporine (1 μM), or actinomycin-D (100 ng/ml) for 18 h, and also culture 
under conditions of serum starvation for 18 h. After treatment, dishes were tapped to dislodge 
weakly adherent cells, and then all detached cells were collected by medium aspiration and 
centrifugation. Separate lysates of the detached and adherent cell populations were prepared and 
analyzed by Western blotting for T-cad and active caspase 3. Regardless of the apoptosis-
inducing condition, there was a consistent 2-3-fold elevation of T–cad expression in detached 
HUVEC, as compared with adherent HUVEC or untreated control HUVEC, and active caspase 3 
was detectable only in detached cell populations (Fig. 1A). Expression of Gα subunit, which 
served as the internal control, remained steady. 
The above experiments might imply up-regulation of T-cad only in apoptotic cells. To 
investigate this issue, immunocytochemical analysis was performed after an abbreviated (4-6 h) 
period of serum deprivation to enable fixation of both adherent HUVEC and those undergoing 
detachment. HUVEC were stained for T-cad using primary anti-T-cad/secondary Cy3-labeled 
antibodies and with Hoechst for nuclear counterstaining (Fig. 1B). An increased intensity of 
staining for T-cad was clearly evident after serum deprivation, which in some cells was also 
associated with nuclear chromatin condensation (i.e., late stages of apoptosis). We could only 
detect a few such apoptotic cells, because in spite of careful handling procedures, most of the 
detaching/apoptotic cells are washed off. Nevertheless, the data demonstrate that T-cad is up-
regulated after apoptosis induction. 
In subsequent experiments, we focused on the response of HUVEC under conditions of serum-
deprivation since this is one of the most widely used and reproducible experimental techniques 
for apoptosis induction in nontransformed cells. 
Serum withdrawal induced apoptosis: T-cad elevation precedes caspase activation 
To determine the kinetics of changes in T-cad expression in response to serum withdrawal, 
HUVEC were serum-deprived for different time intervals, and after removal of detached cells by 
gentle rinsing of culture wells the adherent cell population was lysed and immunoblotted for T-
cad. A transient ~2-fold elevation of T-cad in adherent cells was observed within the first 2-3 h, 
and thereafter levels decreased to ~25% of control levels (Fig. 2A). Alterations in levels of T-
cad, as measured in whole cell lysates reflect changes in surface expression, as verified by an 
increased level of T-cad levels in plasma membrane preparations (29) and by an increased 
immunofluorescence after live cell staining for T-cad (data not shown). Analysis of caspase 
activity in HUVEC cultures (assay including both detached and adherent cells) showed that 
caspase activation began within 4 h after serum withdrawal, reached peak activation at ~6-8 h, 
and then returned to basal levels (Fig. 2B). Permanent loss of attachment to the substratum is 
characteristic of endothelial cell death in vitro, and therefore to obtain an index of cell survival, 
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 the numbers of adherent cells were quantitated at different intervals after serum deprivation. Loss 
of attachment initially occurred after ~4 h and by 6 h, 50% of cells had detached (Fig. 2C). Thus 
serum withdrawal-associated elevation in T-cad levels precedes activation of caspase(s) and cell 
detachment. Comparable results to those described above were obtained with the microvascular 
EC line HMEC-1 (data not shown). 
Involvement of reactive oxygen species in T-cad elevation under conditions of serum 
withdrawal 
Possible mechanism(s) leading to T-cad up-regulation under conditions of serum withdrawal 
were investigated. The ROS generated are causally involved in induction of apoptosis (21, 30), 
and in HUVEC, serum-withdrawal induces oxidative stress (19). Because ROS-induced 
apoptosis in HUVEC is related to reduction of expression of Bcl-2, a survival-associated protein 
(20, 31), we first tested whether the elevation of T-cad expression observed under conditions of 
serum withdrawal was dependent upon Bcl-2 inhibition. HUVEC under normal serum-
containing culture conditions were exposed to HA14-1 (50 μM, 4 h), an inhibitor of Bcl-2 
activity (32). Induction of apoptosis by HA14-1 was confirmed by the presence of active caspase 
3 in both adherent and detached cell populations, but this was not accompanied by an elevation 
of T-cad in either cell population (Fig. 3A). This observation suggests the stimulus for T-cad 
elevation occurs upstream of Bcl-2, and thus we next examined the contribution of ROS. 
HUVEC were incubated either under control serum-containing conditions or serum withdrawal 
conditions without or with inclusion of N-acetylcysteine (NAC; 30 mM), a ROS scavenger (33). 
Adherent cells were analyzed by immunoblotting for T-cad. NAC did not affect T-cad 
expression under control conditions (data only for serum+NAC shown, but not significantly 
different from serum only), but it completely abrogated the stimulatory effect of serum 
deprivation of T-cad expression (Fig. 3B). Interestingly, inclusion of NAC under serum 
withdrawal conditions progressively reduced T-cad expression to levels that were even lower 
than under control culture conditions. As a positive control for the association between T-cad 
expression and ROS, HUVEC were exposed to exogenous H2O2 (1 mM, 4 h) under normal 
serum-containing conditions without or with inclusion of NAC. Direct induction of oxidative 
stress by H2O2 resulted in an increased expression of T-cad in adherent HUVEC (and HEMC-1 
cell line, data not shown), which could be completely inhibited by NAC (Fig. 3C). 
To shed some light on the endogenous source of ROS leading to T-cad up-regulation under 
conditions of serum withdrawal, HUVEC were subjected to serum deprivation for 4 h in the 
presence of either diphenyleneiodonium (DPI), an inhibitor of flavin-containing oxidases, among 
them NADPH oxidase and xanthine oxidase, rotenone, the mitochondrial (complex I) NADH 
dehydrogenase inhibitor, antimycin A, the mitochondrial (complex III) cytochrome b-c1 
inhibitor, and N-monomethyl-L-arginine (L-NAME), a nitric oxide synthase inhibitor. Western 
blot analysis of adherent cells showed that the serum withdrawal-induced increase in T-cad 
levels was sensitive to inhibition by DPI, but not by rotenone, antimycin A or L-NAME (Fig. 
3C). 
T-cadherin overexpression protects HUVEC from serum withdrawal-induced apoptosis 
Because T-cad elevation in adherent HUVEC under conditions of serum withdrawal precedes 
caspase activation and T-cad levels were high in detached HUVEC, it is possible that T-cad 
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 serves some proapoptotic function. However, ROS can elicit both apoptosis and survival signals, 
and our previous studies demonstrated that overexpression of T-cad in HUVEC increases their 
proliferative and migratory potential (13, 16). We investigated whether the up-regulation of T-
cad, which occurs in HUVEC following serum withdrawal might represent a survival response. 
The time course of caspase activation (using fluorimetric caspase assay) in response to serum 
withdrawal in parental HUVEC (P) and HUVEC infected with empty (E) or T-cad (T-cad+)-
containing adenoviral particles was compared. T-cad overexpression did not influence basal 
caspase activity under control serum-containing culture conditions, but following serum-
deprivation, the degree of caspase activation was significantly blunted in T-cad+-HUVEC as 
compared with P- and E- HUVECs (Fig. 4A). We also examined whether overexpression of T-
cad might protect HUVEC from apoptosis induced by TNF-α, staurosporine, or actinomycin-D. 
Caspase activity was assayed in P-, E-, and T-cad+- HUVEC after exposure to these compounds 
for 6 and 12 h. Parallel wells subjected to serum deprivation served as the positive apoptosis 
experimental control. Whereas a protective effect of T-cad overexpression was evident at both 6- 
and 12-h periods in serum-deprived cultures, in the case of TNF-α, staurosporine, or 
actinomycin-D protection against apoptosis was significant only at the 12-h period (Fig. 4B). 
Determination of the number of adherent cells after 8 h of incubation in the presence of TNF-α, 
staurosporine, or actinomycin-D revealed a significantly greater number for T-cad+ -HUVEC 
than for P- and E-HUVEC (Fig. 4C). Taken together, the data indicate that up-regulation of T-
cad can augment cell survival under different conditions of stress. 
Signaling pathway(s) mediating T-cad-dependent protection against stress-induced 
apoptosis 
The next series of experiments were aimed at determining the signal pathway(s) through which 
T-cad might mediate its survival effects. The PI3K/Akt/mTOR signal cascades are major effector 
pathways mediating survival signals downstream of oxidative stress (9, 24, 27). To assess their 
potential involvement in the survival/apoptosis protection effects P-, E- and T-cad+- HUVEC 
were serum-deprived in the absence or presence of either wortmannin, a PI3K inhibitor or 
rapamycin, a mTOR inhibitor. As expected (34), wortmannin concomitantly increased caspase 
activation (Fig. 5A) and decreased cell survival (Fig. 5B) in all HUVECs under both serum-
containing (P<0.01) serum withdrawal (P<0.001) culture conditions. However, PI3-kinase 
inhibition abrogated the blunted apoptosis response of T-cad+-HUVEC to serum-deprivation; 
caspases activity and cell survival were comparable between T-cad+-, P- and E-HUVECs (Fig. 
5). Inhibition of mTOR also abrogated the blunted apoptosis response of T-cad+-HUVEC to 
serum-deprivation (Fig. 5). These observations indicate that T-cad might signal through the 
PI3K/Akt/mTOR cascades. We next examined the phosphorylation status of PI3K target Akt in 
P-, E-, and T-cad+-HUVEC under serum- and serum deprivation (6 h) conditions. p-Akt in all 
cells was significantly reduced following serum deprivation, but for both culture conditions T-
cad+ cells exhibited a significantly higher level of p-(Ser473)Akt than the control HUVECs (Fig. 
6A). To verify the apparent “hyper”-activation of the PI3K/Akt pathway in T-cad+-HUVEC, we 
determined the phosphorylation status of p70S6K, a downstream target (via mTOR) of Akt (35). 
Serum deprivation significantly decreased the levels of p-p70 S6K in P-, E-, and T-cad+-HUVEC. 
However, under both serum-containing and serum deprivation conditions, the level of p-p70S6K 
cells in T-cad+-HUVEC was significantly higher compared with P- and E-HUVECs (Fig. 6B). 
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 Because a reciprocal relationship between the PI3-kinase/Akt survival pathway and the p38 
MAP kinase proapoptotic pathway has been demonstrated (34, 36, 37), we examined whether T-
cad overexpression might concomitantly affect p38 MAPK phosphorylation. Serum deprivation 
significantly increased levels of p-p38 in all HUVEC, but in T-cad+-HUVEC, the levels of p-p38 
under both serum-containing and serum deprivation conditions were significantly lower 
compared with P- and E-HUVECs (Fig. 6C). 
To confirm that T-cad overexpression transmits survival signals through the PI3K/Akt/mTOR 
pathways, we analyzed the phosphorylation status of Akt, p38 and p70 S6K, as well as the levels 
of active caspase 3, after incubation of cells for 6 h under serum-containing and serum-free 
conditions and without or with inclusion of wortmannin (PI3K inhibitor) and rapamycin (mTOR 
inhibitor). As expected wortmannin reduces levels of p-Akt regardless of culture condition; 
however, whereas in the presence of serum, p-Akt remained higher in T-cad+-HUVEC (vs. P- 
and E-HUVEC), under conditions of serum withdrawal in the presence of serum, p-Akt in all 
HUVECs was reduced to a similar, very low level (Fig. 7A). In the case of p38, the inverse was 
true. Wortmannin increased p-p38 levels regardless of culture condition; however, in the 
presence of serum, p-p38 remained lower in T-cad+-HUVEC (vs. P- and E-HUVEC), whereas 
under conditions of serum withdrawal p-p38 in T-cad+-HUVEC increased to levels comparable 
at least with E-HUVEC (Fig. 7A). Rapamycin completely inhibited phosphorylation of p70S6K in 
all cultures thus effectively eliminating the typical differential in p-p70S6K between T-cad+-
HUVEC and P- and E-HUVECs (Fig. 7B). However, rapamycin did not completely normalize p-
p38. Levels of total Akt, p38, and p70 were not affected by culture conditions without or with 
inclusion of wortmannin and rapamycin (Fig. 7). Active caspase 3 was not detectable in any of 
the cultures under serum-containing conditions, either with or without wortmannin (Fig. 7A) or 
rapamycin (Fig. 7B). After serum withdrawal, active caspase 3 was present in P- and E-
HUVECs, but barely detectable in T-cad+-HUVEC. The protective effect of T-cad 
overexpression on serum withdrawal-induced apoptosis was blocked by inclusion of wortmannin 
or rapamycin, whereby levels of active caspase 3 were comparable between T-cad+ and P- or E-
HUVECs (Fig. 7). Inclusion of NAC did not eliminate the signaling differential between T-cad+-
HUVEC and P- or E- HUVECs under serum or serum-withdrawal conditions (analysis 
performed only with respect to p-Akt/Akt, p-p38/p38, and caspase 3, data not shown). Taken 
together, these data indicate that overexpression of T-cad leads to a concurrent potentiation of 
the PI3K/Akt/mTOR survival pathways and repression of the p38 MAPK pro-apoptotic pathway. 
Finally, we investigated the potential contribution of other survival/death pathways, including 
extracellular signal-related kinase ERK1/2, stress-activated protein kinase JNK/SAPK1 (27), 
FAK (38), Bcl-XL (39), p21 (40), and survivin (41). T-cad+ and P- or E-HUVECs did not differ 
with respect to either total levels or the phosphorylation status of ERK1/2, JNK/SAPK1, and 
FAK under serum or serum withdrawal (6 h) conditions, and neither were any differences 
detectable for p21, Bcl-XL or survivin (Fig. 7C). These pathways thus appear not to contribute to 
the prosurvival properties of T-cad overexpression. However, it is possible that under other 
experimental conditions, evidence for involvement of one or more of these pathways might 
emerge. 
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 DISCUSSION 
This study has examined whether there is a functional relationship between oxidative stress, T-
cad expression, and cell survival status. Oxidative stress is an important determinant in the 
pathophysiology of atherosclerosis, restenosis, and angiogenesis, and the mechanisms by which 
oxidative stress mediates alterations in vascular cell function are complex. The outcome of 
oxidative injury varies with cell type, oxidative agent, and also with the extent and duration of 
injury. Furthermore, ROS are capable of eliciting both apoptosis and survival signals which can 
result in a wide range of responses encompassing proliferation, growth arrest, cell survival, and 
cell death (24, 26). Our investigation shows that ROS contribute to stress-induced elevation in T-
cad on HUVEC and that overexpression of T-cad in HUVEC protects against stress-induced 
apoptosis through concomitant activation of the PI3K/Akt/mTOR survival signal pathways and 
suppression of the p38 MAPK proapoptotic pathway (Fig. 8). 
Indirect evidence for a relationship between oxidative stress, T-cad expression, and apoptosis 
was obtained from experiments demonstrating a 2-3-fold up-regulation of T-cadherin in 
apoptotic HUVEC under a variety of conditions known to induce oxidative stress, including 
serum withdrawal (19) or exposure to TNF-α (42), staurosporine (43), actinomycin-D (44), and 
high glucose (45). A role for ROS in up-regulation of T-cad was directly supported by the ability 
of the potent antioxidant N-acetylcysteine (33) to completely abrogate both serum withdrawal- 
and H2O2-induced up-regulation of T-cad. Our observation of inhibition of the serum 
withdrawal-induced increase in T-cad by DPI suggests that the principle source of ROS derives 
from flavin-containing oxidases (which could include NAD(P)H oxidase and xanthine oxidase) 
(24, 33). Transcriptional mechanisms regulating T-cad expression in response to oxidative stress 
are not yet known. 
The data showing increased T-cad in detached, apoptotic HUVEC populations and that serum 
withdrawal-induced T-cad up-regulation occurs within the adherent monolayer prior to caspase 
activation and cell detachment could be interpreted to indicate proapoptotic functions for T-cad. 
However, such an interpretation is in contradiction to our previous demonstration of enhanced 
proliferation potential in HUVEC and SMC that overexpress T-cad (13, 16). We therefore 
considered that elevation of T-cad in HUVEC under conditions accompanied by oxidative stress 
may rather represent a survival response and addressed this issue by examining the influence of 
T-cad overexpression on sensitivity to serum deprivation-induced apoptosis and signal 
transduction. 
First evidence of some prosurvival function of T-cad was obtained by the experiments 
demonstrating that HUVEC overexpressing T-cad exhibited significantly reduced caspase 
activation and concomitant increased cell survival to not only serum deprivation, but also to 
TNF-α, staurosporine, and actinomycin-D. Further support that T-cad may function in cell 
survival was derived from experiments demonstrating participation of PI3K/Akt/mTOR cascade, 
which is a major survival signaling pathway in many cell types, including EC (24, 26, 27, 35). 
First, we observed higher phosphorylation levels (without a change in total protein) of both PI3K 
target Akt and mTOR target p70S6K in T-cad+ HUVEC under both serum-containing and serum-
deprived culture conditions provide that T-cad might signal through the PI3K/Akt/mTOR 
cascade. Second, under serum-deprived conditions, levels of active caspase 3, caspases activity, 
as well as cell survival were normalized (between T-cad+-, P- and E-HUVECs) by inclusion of 
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 either PI3K inhibitor (wortmannin) or mTOR inhibitor (rapamycin). “Constitutive” (i.e., under 
normal serum-containing conditions) hyperactivation of the PI3K/Akt/mTOR pathway in T-cad+ 
HUVEC may endow these cells with an improved ability to resist induced apoptosis, as 
evidenced by the almost negligible presence of active caspase 3 following serum deprivation. 
Because the PI3K/Akt/mTOR cascade is also important for driving G1-S cell cycle progression, 
its hyperactivation in T-cad+ HUVEC might clarify our earlier finding of their increased 
proliferation potential (16). 
Of other herein studied MAPK and SAPK pathways that can modulate cell survival and are 
affected by oxidative stress (i.e., ERK1/2, JNK/SAPK1, and p38 MAPK/SAPK2), T-cad 
overexpression affected only p38 MAPK/SAPK2, which is an important modulator of the 
proapoptotic pathway in various cell types, including EC (34, 36, 37). Our results showing that 
the phosphorylation level of p38 is reduced in T-cad+ HUVEC under both serum-containing and 
serum-deprived culture conditions, provide additional evidence for survival effects due to T-cad 
overexpression The “constitutive” suppression of p38 MAPK in T-cad+ could confer an 
apoptosis resistance additional to that afforded by hyperactivation of the PI3K/Akt/mTOR 
cascade. Wortmannin, but not rapamycin, caused near normalization (between T-cad+ and 
control HUVECs) of p38 phosphorylation, which is consistent with previous studies 
demonstrating cross-talk between PI3K/Akt and p38 MAPK pathways in HUVEC (34, 36, 37). 
Antiapoptotic effects involving PI3K/Akt activation have also been shown for N-, E- and VE-
cadherins. Homophilic cadherin engagement-dependent survival signals mediated downstream of 
PI3K/Akt activation are diverse. These include stabilization of antiapoptotic Bcl-2 protein 
expression for N-cadherin in prostate carcinoma cells (46); either down-regulation of 
proapoptotic MEK/ERK1/2 in intestinal epithelial cells (47) or up-regulation of MEK/ERK1/2 
and Bcl-2 in squamous carcinoma cells (48) for E-cad; and down-regulation of proapoptotic 
p53/p21 (49) and of survivin (50) for VE-cadherin in endothelial cells. The mechanisms of signal 
transmission are likely to be distinct from those used by T-cad. For N-, E- and VE-cadherins, 
Akt activation depends upon homophilic adhesion interactions and requires association of PI3K 
with the cadherin-catenin-cytoskeletal complex (46, 47, 49). The prosurvival effects 
demonstrated in this study were not dependent on confluency (i.e., all experiments performed on 
cultures at ≈60–80% confluency). Moreover, T-cad lacks the transmembrane and cytoplasmic 
domains necessary for catenin mediated linkage to the cytoskeleton, and does not mediate 
homophilic intercellular adhesion (2, 13). It can be speculated that T-cad-dependent signaling 
occurs because of its location within rafts (51), in which diverse signaling molecules 
compartmentalize and can be variously assembled to generate specific signaling platforms (52). 
The molecular adaptors with which T-cad must coassemble or interact in order to effect 
intracellular signaling have not yet been investigated. 
In conclusion, we demonstrated that 1) T-cad is up-regulated in EC in response to oxidative 
stress (i.e., serum deprivation) via flavin-containing oxidases and 2) T-cad overexpression in EC 
can elicit survival signaling responses that protect against stress-induced apoptosis. T-cad may 
thus contribute to regulation of tissue cellularity not only by stimulating endothelial cell 
proliferation and migration (13, 16), but also by promoting cell survival under stress conditions. 
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Fig. 1 
 
 
 
                                    
Figure 1. T-cadherin expression is up-regulated in HUVEC in response to stress. A) HUVEC under normal serum-
containing conditions were either cultured for 72 h in the presence of 30 mM glucose (gluc.), or exposed for 18 h to 40 
ng/ml TNF-α (TNF), 1 µM staurosporine (stau.), or 100 ng/ml actinomycin-D (Act.), or cultured for 18 h under serum-
withdrawal conditions (DMEM+0.1% BSA; SF). Adherent and weakly adherent/detached cell populations (indicated by A 
and D, respectively in blot images) were separately collected and analyzed by immunoblotting for T-cad (105/130 kDa), 
active caspase 3 (17/19 kDa) and G-α subunit (internal standard; 42 kDa)). There were no detached cells in control cultures 
(serum-containing; control or C). **Significant difference (P at least <0.0.1) from control. B) Immunocytochemistry of 
HUVEC under normal serum-containing conditions (Serum) and after 4-6 h serum deprivation (Serum-free) using antibody 
against T-cad (or nonimmune rabbit IgG, n/i) and Hoechst, as described in Materials and Methods. Images were captured 
at two different magnifications (see scale bars). Late-stage apoptotic cells (i.e., with nuclear chromatin condensation) are 
indicated with arrows. 
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Figure 2. Serum starvation-induced up-regulation in T-cad expression precedes activation of caspase and cell detachment. 
A) Adherent HUVEC were lysed at indicated time intervals after serum withdrawal and analyzed for T-cad expression.  
B) Caspase activity was assayed fluorimetrically in HUVEC (including both adherent + detached populations) cultured in 
the presence and absence of serum. C) Cell survival was evaluated after rinsing of culture dishes by enumeration of 
adherent HUVEC. Asterisks indicate significant difference: *P < 0.05 and **P at least <0.01 from zero time controls. 
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Figure 3. Serum starvation-induced changes in T-cad are independent of Bcl-2 inhibition but dependent upon ROS. A) 
HUVEC under normal serum-containing conditions were incubated for 4 h without (control) or with inclusion of 50 µM 
HA14-1; separately prepared lysates of adherent and detached cell populations were immunoblotted for T-cad and active 
caspase 3. The experiment was performed twice with comparable results. B) Lysates of adherent HUVEC were 
immunoblotted for T-cad following culture for the indicated times under normal serum-containing and serum withdrawal 
conditions without or with inclusion of 30 mM NAC. The experiments were performed with interval series of either 0, 2, 4, 
6, 8, 12, and 24 h or 0, 3, 6, 9, 12, and 24 h. Changes in T-cad protein expression are expressed relative to that at time 0 
(arbitrarily taken as 100%), and the histogram presents combined data from both of the series. A representative blot from a 
single experiment is shown. C) HUVEC were incubated for 4 h either under serum-containing conditions in the absence 
(control) or presence of 1 mM H2O2 and without or with inclusion of 30 mM NAC, or under serum-deprived (SD) 
conditions without or with inclusion of 30 mM NAC, 10 µM DPI, 10 µM antimycin A, 10 µM rotenone or 1 mM L-NAME. 
Lysates of adherent cells were immunoblotted for T-cad and Gα. **Significant difference (P<0.01; n=3). 
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Figure 4. T-cad overexpression in HUVEC protects against apoptosis. A) Parental, empty-vector and T–cad+ HUVECs 
were incubated under serum-free conditions and fluorimetrically assayed for caspases activity at the indicated times. 
Parental HUVEC maintained under normal serum-containing culture conditions served as the negative assay control.  
B) Caspases activity was measured following incubation for 6 and 12 h either under serum-free conditions, or under serum-
containing conditions in the presence of staurosporine (1 µM), TNF-α (40 ng/ml), or actinomycin-D (100 ng/ml).  C) Cell 
survival of following 8 h incubation under the same conditions as in B was evaluated by enumeration of the adherent cells; 
cell numbers are expressed relative to those in serum-containing controls (arbitrarily taken as 100%). Asterisks indicate 
where T-cad+ differ significantly from parental and empty-vector cultures (*P<0.05, **P at least <0.01). There were no 
significant differences between parental and empty-vector HUVECs following serum deprivation or treatment with the 
apoptosis-inducing compounds. 
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Figure 5. Effect of PI3K inhibition on caspases activation in control and T-cad overexpressing HUVEC. Caspases activity 
(A) and cell survival (B) was determined in parental, empty- and T-cad overexpressing (T-cad+) HUVEC following 
incubation for 6 h either in the presence (S) or absence of serum (SF), and without or with inclusion of 10 nM wortmannin 
(wort) or 10 nM rapamycin (rapa). For each cell type, changes in caspases activity and cell survival are expressed relative 
to their respective serum controls. **T-cad+ differs significantly (P<0.01) from parental and empty. There were no 
significant differences between parental and empty. 
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Figure 6. Overexpression of T-cad in HUVEC leads to hyperactivation of Akt signaling and reduced activation of p38. 
Lysates of parental, empty-vector, and T–cad+ HUVEC incubated for 6 h under normal serum-containing and serum-free 
conditions were immunoblotted for total Akt/phospho-Akt (60kDa; A), total p70S6K/phospho-p70S6K (70 kDa; B), and 
p38/phospho-p38 (43 kDa; C). Parental, empty-vector, and T-cad+ HUVEC did not differ with respect to total Akt, p70S6K 
and p38 levels under either serum-containing or serum-withdrawal conditions. Ratios of total protein/phosphorylated 
protein are given. Representative blots are presented. Asterisks indicate where T-cad+ HUVEC differ significantly 
(*P<0.05, **P at least <0.01) from parental and empty-vector HUVECs. There were no significant differences between 
parental and empty-vector HUVECs under either of the culture conditions. 
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Figure 7. T-cad overexpression rescues HUVEC from serum deprivation-induced apoptosis via PI3 kinase/Akt/mTOR 
pathway. Parental (P), empty (E), and T-cad overexpressing (T) HUVEC were incubated for 6 h either in the presence or 
absence of serum (A–C), and without or with inclusion of 10 nM wortmannin (A) or 10 nM rapamycin (B). Cell lysates 
were prepared and immunoblotted for T-cad, active caspase 3, Akt/phospho-Akt, p38/phospho-p38, p70S6K/phospho-
p70S6K, Erk1/2/phospho-ERK1/2 (42/44 kDa), JNK1/phospho-JNK1 (46/56 kDa), FAK/phospho-FAK (125 kDa), BCL-XL 
(30 kDa), p21 (21 kDa), and survivin (16 kDa). G-α served as the internal loading control. P, E and T did not differ with 
respect to total Akt, p70S6K, p38, Erk1/2, JNK1, or FAK levels under any of the experimental conditions. §, numbers below 
the blots (mean values) indicate band intensities relative to that (arbitrarily taken as 1) in parental HUVEC under normal 
serum-containing culture conditions. Quantitative data for C are not shown as there were no differences between P, E, and 
T. Asterisks indicate where expression level in T differed significantly (P at least <0.01) from P and E. There were no 
significant differences between P and E under any of the experimental conditions. 
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Fig. 8 
 
 
 
Figure 8. Proposed role of T-cad as a survival protein. Expression of T-cad in HUVEC is increased in response to reactive 
oxygen species generated during stress (e.g., serum-deprivation) and protects against apoptosis via activation of the 
PI3K/Akt/mTOR survival pathways and concomitant suppression of the p38 MAPK proapoptotic pathway. 
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3.2. T-cad and molecular mediators  
 
 
The results of this project have been recently accepted by FASEB J for publication. 
 
Integrin-linked kinase is an essential mediator for T-cadherin-
dependent signaling via Akt and GSK3β in endothelial cells. 
 
(The accepted manuscript is appended) 
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ABSTRACT 
 
Glycosylphosphatidylinositol-anchored T-cadherin (T-cad) influences several parameters of 
angiogenesis including endothelial cell (EC) differentiation, migration, proliferation and survival. 
This presupposes signal transduction networking via mediatory regulators and molecular adaptors 
since T-cad lacks transmembrane and cytosolic domains. Here, using pharmacological inhibition 
of PI3K, adenoviral-mediated T-cad-overexpression, siRNA-mediated T-cad-depletion and 
agonistic antibody-mediated ligation we demonstrate signaling by T-cad through PI3K-Akt-
GSK3β pathways in EC. T-cad-overexpressing EC exhibited increased levels and nuclear 
accumulation of active β-catenin, which was transcriptionally active as shown by increased 
Lef/Tcf reporter activity and elevated levels of cyclin D1 mRNA and protein. Co-transduction of 
EC with constitutively active GSK3β (S9A-GSK3β) abrogated stimulatory effects of T-cad 
active β-catenin accumulation, proliferation and survival. Integrin-linked kinase (ILK), a 
membrane proximal upstream regulator of Akt and GSK3β, was considered a candidate signaling 
mediator for T-cad. T-cad was present in anti-ILK immunoprecipitates and confocal microscopy 
revealed co-localization of T-cad and ILK within lamellipodia of migrating cells. ILK-siRNA 
abolished T-cad-dependent  effects on ser473Akt/ser9GSK3β phosphorylation, active β-catenin 
accumulation and survival. We conclude ILK is an essential mediator for T-cad signaling via Akt 
and GSK3β in EC. This is the first demonstration that ILK can regulate inward-signaling by GPI-
anchored proteins. Further, ILK-GSK3β-dependent modulation of active β-catenin levels by GPI-
anchored T-cad represents a novel mechanism for controlling cellular β-catenin activity. 
 
Key words: GPI-anchored protein, signal transduction, active β-catenin accumulation, 
proliferation, survival. 
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INTRODUCTION 
 
T-cadherin (T-cad), an atypical member of the cadherin superfamily, is widely expressed in the 
cardiovascular system. Expression of T-cad in vascular cells is markedly increased during 
atherosclerosis (1), restenosis after balloon angioplasty (2) and tumour neovascularisation (3). 
Accumulating data supports that T-cad participates in several processes (e.g. differentiation, 
migration, proliferation and survival) that occur during vascular remodelling and angiogenesis. In 
vitro, homophilic ligation of T-cad on the endothelial cell (EC) surface with soluble recombinant 
T-cad or with agonistic antibodies induces the motile phenotype via activation of Rho and Rac 
pathways (4, 5), facilitates cell migration (5) and  stimulates in-gel outgrowth of endothelial 
sprouts in 3-dimensional EC-spheroid and heart tissue models of angiogenesis (6). In vivo, 
myoblast-mediated delivery of recombinant soluble T-cad to mouse skeletal muscle facilitates 
VEGF-induced angiogenesis (6). Moreover, T-cad expression in EC and aortic smooth muscle 
cells (SMC) is dynamically regulated during the cell cycle, and adenoviral-mediated 
overexpression of T-cad in EC and SMC promotes cell cycle progression and proliferation (7). 
Upregulation of T-cad in EC occurs in vitro in response to oxidative stress and adenoviral-
mediated overexpression protects against oxidative stress-induced apoptosis (8). 
 
Signal transduction pathways mediating the effects of T-cad on vascular cell differentiation, 
migration, proliferation and survival are not well delineated. T-cad overexpression is 
accompanied by activation of the PI3-kinase/Akt/mTOR/p70S6 kinase axis (8). T-cad ligation, 
which in EC induces cell polarization and angiogenic switching and increases cell motility (5) 
also leads to activation of Akt (6). Ligation-dependent effects of T-cad on EC motility require 
activation of RhoA/ROCK and Rac (4). T-cad–promoted survival was found to be associated 
with concomitant PI3K-dependent activation of the PI3K/Akt/mTOR survival signal pathway and 
suppression of the p38 MAPK proapoptotic pathway (8); this might reflect a cross-talk between 
p38 MAPK and Akt  (9) or involvement of other upstream regulators  of p38 MAPK (e.g. small 
GTPases (10), integrin-linked kinase (ILK) (11)).  
 
The multiple effects of T-cad on EC behavior presuppose signal pathway intersection and 
networking. GSK3β is a multifunctional serine/threonine kinase that serves a pivotal point of 
convergent signaling pathways in EC to control angiogenic responses, including proliferation, 
migration and survival (12, 13). Akt-catalyzed phosphorylation of ser-9 on GSK3β leads to its 
inhibition and in a cascade affects the functionality of diverse GSK3β substrates including 
metabolic and signaling proteins, structural proteins and transcription factors (14, 15). Several 
other kinases including protein kinase A, protein kinase C and p70S6 kinase can modulate 
activity of GSK3β by phosphorylation on ser-9 (14, 15). ILK, although lacking critical consensus 
sequences of Ser/Thr kinases in the ILK kinase domain, has also been shown to have PI3K-
dependent kinase activity toward GSK3β on ser-9 (16, 17). ILK can associate with some 
components of the Wnt signaling pathway (18, 19). This association can modulate acute 
canonical Wnt signaling and β-catenin stabilization in a PI3K-GSK3β-independent manner (19). 
On the other hand prolonged Wnt signaling was proposed to lead to growth factor activation of 
the PI3K-ILK-GSK3β  signaling axis (19).  
 
How T-cad might transduce its signals to intracellular effectors is currently unknown. T-cad 
shares the general molecular organization of cadherin extracellular domains, but lacks 
transmembrane and cytoplasmic domains and is attached to the plasma membrane via a 
glycosylphosphatidylinositol (GPI) anchor (20). Signaling by GPI-anchored proteins is thought to 
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require their interaction with adaptor molecules within plasma membrane lipid rafts (21, 22), 
where GPI-anchored proteins, including T-cad (23) are preferentially localized.  
 
In this study we aimed to further delineate proliferation and survival signal transduction 
mechanisms activated by T-cad in EC, and to identify a membrane proximal molecule that could 
mediate inward signal transmission by GPI-anchored T-cad. 
 
 
 
MATERIALS AND METHODS 
 
Cell culture: Human umbilical vein endothelial cells (HUVEC) (PromoCell GmbH, Heidelberg, 
Germany) were cultured in low serum (2%)-containing EC growth medium (PromoCell). All 
tissue culture surfaces were pre-coated with 0.1% gelatine, and HUVEC were used at passages 2-
4 during which expression of markers (von Willebrand factor, CD 31, VE-cadherin) for 
differentiated EC remained steady. Human microvascular EC line HMEC-1 (24) was cultured in 
the same medium supplemented with 10% FCS.  
 
Reagents and antibodies: PI3K inhibitor LY294002 was from Sigma-Aldrich (Buchs, 
Switzerland). GSK3 fusion protein was from Cell Signaling Technology Inc. (Danvers, MA., 
USA). Transfection of siRNA was carried out using siPORT Lipid (Ambion (Europe), 
Cambridgeshire UK). Protein G Sepharose beads were from Amersham Biosciences (Little 
Chalfont, UK). The following antibodies were used: polyclonal antibody against the first 
extracellular domain of T-cad generated in our laboratory (25), anti-Akt, anti-phospho-
(Ser473)Akt, anti-GSK3β and anti-phospho-(Ser9)GSK3β (Cell Signaling, New England Biolabs 
GMBH, Frankfurt, Germany), anti-β-catenin, anti-active β-catenin (ABC) (Upstate Cell 
Signaling Solutions, Lake Placid, NY, USA), anti-ILK (clone 65.1, Sigma-Aldrich and clone 
65.1.9, Upstate), anti-cyclin D1 (BD Biosciences), anti-β-actin (Santa Cruz Biotechnology Inc., 
Santa Cruz, California, USA). Anti-rabbit and anti-mouse secondary antibodies coupled to 
horseradish peroxidase were from Southern Biotechnologies (BioReba AG, Reinach, 
Switzerland). Secondary anti-species Cy-2- and Cy3-labelled IgG were from Jackson 
ImmunoResearch Laboratories (West Grove, USA). Amersham ECL, Pierce (Rockford, Ill., 
USA) Enhanced Luminescence System or Pierce SuperSignal West Dura were variously used for 
detection of immunoreactive proteins.  
 
Adenoviral infection: Adenoviral vectors encoding wild type GSK3β (wt-GSK3β) was a kind 
gift of Dr. Morris Birnbaum (University of Pennsylvania, Philadelphia, USA). Catalytically 
inactive GSK3β (KM-GSK3β) and non-phosphorylatable constitutively active mutant of GSK3β 
(S9A-GSK3β) were a kind gift of Dr. Kenneth Walsh (Tufts University, Boston, MA, USA). 
Adenoviral vector encoding T-cad has been described previously (5, 7). All constructs were 
amplified in HEK293 cells and purified by ultracentrifugation. Viral titers were determined as 
PFUs (5, 7).  For infection, HUVEC were typically incubated with adenovirus at a multiplicity of 
infection (MOI) 50-100 for 12h. Under these conditions, the transfection efficiency was greater 
than 90%. 
 
siRNA transfection: Short interfering RNAs (siRNA) for T-cad (5’-
GGACCAGUCAAUUCUAAACtt (26)) and ILK ((5'-CCCGGCUCAGGAUUUUCUCtt (27)) 
were purchased from Microsynth (Balgach, Switzerland). Equal amounts of complementary RNA 
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oligonucleotides were combined to a final concentration of 20 mM and annealed according to the 
protocol supplied by the manufacturer. RNA oligos 5’CUCUGUUCGUCCAUGCACGga and 
5’AAGGUGGUUGUUUUGUUCAtt were used as negative controls for T-cad and ILK siRNA, 
respectively; neither of these siRNAs affected expression of either T-cad or ILK at both 
transcriptional and protein levels. Transfection of HUVEC with siRNA’s was performed using 
Si-PORT Lipid (Ambion (Europe) Ltd., Huntingdon, Cambridgeshire, UK) according to 
manufacturer's recommendations, and unless otherwise stated, cells were analysed 48-72h post-
transfection. The efficiency of ILK and T-cad silencing, routinely determined by 
immunoblotting, ranged between 70-80%.  
 
Reporter gene analysis: Reporter plasmids for Lef/Tcf transcription factors (Bat-Lux) were a 
kind gift from Dr. Stefano Piccolo (University of Padua, Italy). Bat-Lux plasmid constitutes 
seven repeats of Tcf binding element and siamois minimal, cloned upstream of Luciferase gene in 
pGL3 backbone. 16h after infection of HMECs with empty and T-cad-containing adenovirus 
cells were co- transfected with either pGL3 orBat-Lux constructs and pRLTK vector as an 
internal transfection control using Lipofectamine 2000TM.. Luciferase activity was determined 
after 48h using Dual Luciferase Assay Kit (Promega, Madison, WI, USA). 
  
RNA extraction and reverse transcription polymerase chain reaction: Isolation of mRNA, 
reverse transcription, and real-time PCR analysis were performed as described previously (6). 
Cyclin expression was normalized to the expression of GAPDH gene. Primer sequences were as 
follows:  5’-CGTGGCCTCTAAGATGAAGGA-3’ forward and 5’-
CGGTGTAGATGCACAGCTTCTC-3’reverse for cyclin D1; 5’-
TCATGACCACAGTCCATGCC-3’ forward and 5’-GCCATCCACAGTCTTCTGGGT-3’ 
reverse for GAPDH. 
 
Cell proliferation and survival assays: Proliferation was determined by cell enumeration as 
described previously (7). Survival response to serum deprivation (6h culture in medium 
containing 0.1%BSA instead of 2%FCS) was assayed using a fluorimetric caspase assay kit 
(Homogeneous caspases assay; Roche Diagnostics GmbH, Mannheim, Germany) as detailed 
previously (8). Caspases activity, measured as arbitrary fluorescence units (au.) per 2x104cells, is 
expressed relative to activity in respectively control-transduced cells.  
 
Immunofluorescence microscopy: Immunofluorescence techniques have been described in 
detail previously (4, 28). Briefly, HUVEC were plated at a density of 105cells/well onto 0.5% 
gelatine-precoated round 12-mm glass coverslips in 24-well plates. Unless otherwise specified 
stainings were performed on fixed (4% paraformaldehyde) and permeabilized (0.1% Triton X-
100) cells. Cells were sequentially incubated with primary antibodies (anti-ABC, anti-ILK or 
anti-T-cad) and secondary anti-species Cy-2- and Cy3-labelled IgG. For non-specific controls, 
non-immune species IgG substituted primary antibodies. Coverslips were mounted upside-down 
on slides using FluorSaveTM reagent (Calbiochem, Darmstadt, Germany). Single-stained 
samples were studied under a Zeiss Axiophot fluorescent microscope (Zeiss, Feldbach, 
Switzerland), and photos were taken using a digital camera and AnalySIS software (Soft Imaging 
System GmbH, Munich, Germany). Double-stained samples were examined using a laser 
scanning confocal microscope LSM 5410 (Zeiss, Feldbach, Switzerland). Images were processed 
any analysed for colocalization on an O2 Workstation (Silicon Graphics Computer Systems, 
Mountain View, CA, USA) using Imaris 3.0 and Colocalization Bitplanes Software (Bit plane 
AG, Zurich, Switzerland). Micrographs present typical images. 
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Co-immunoprecipitation: Subconfluent HUVEC in 10cm dishes were infected with empty or 
T-cad-containing adenovirus. After 48h cells were washed twice with PBS and lysed by 
incubation for 2h at 4°C in buffer (0.7ml/dish) containing 100mM NaCl, 50mM Tris-HCl, pH 
8.0, 1% Triton X-114, 0.2% SDS, 5mM CaCl2, Complete Mini protease inhibitor cocktail 
(Roche). Lysates were centrifuged (16000g, 10min, 4°C) and supernatants precleared with mouse 
non-immune IgG (50μg/ml) overnight at 4°C. Non-immune IgG were precipitated by mixing 
with protein G-Sepharose 4 FastFlow beads (30μl/sample) for 2h at 4°C and centrifuging for 30s 
at 16000g. Supernatants were incubated with anti-ILK or non-immune IgG (as control) (15μg/ml) 
overnight at 4°C following precipitation with protein G-Sepharose beads and centrifugation as 
described above. Supernatants were discarded, agarose beads were washed thrice with 1ml of 
PBS and 80μl of 2xLaemmli sample buffer was added to the pelleted beads. Samples were 
analysed for T-cad by immunoblotting.  
 
In vitro ILK assay: ILK pull-down was performed as described (16, 17) with minor 
modifications. Cell lysis was performed directly on the plates with lysis buffer (150mM NaCl, 
1% NP-40, 0.5% sodium deoxycholate, 50mM HEPES, pH 7.5, and proteases mixture inhibitor 
(Roche). Equivalent lysate concentrations (determined using the Lowry method) were precleared 
with nonspecific IgG as above, and supernatants immunoprecipitated with anti-ILK antibody 
overnight at 4°C. Protein G Sepharose was added and after 4h ILK immune complexes were 
collected, washed twice with lysis buffer and twice with kinase wash buffer (10mM MgCl2, 
10mM MnCl2, 50mM HEPES, pH 7.5, 0.1mM sodium orthovanadate, 1mM dithiothreitol). The 
washed  pellet was suspended in 25µl kinase assay buffer (10mM MgCl2, 10mM MnCl2, 5 mM 
HEPES, pH 7.5, 1mM sodium orthovanadate, 2mM NaF, 200μM ATP), containing 2.5μg of 
GSK-3 fusion protein as substrate (29), and incubated for 30min at 30°C. The reaction was 
terminated by adding an equal volume of 2x SDS loading buffer and phosphorylation of the 
substrate was detected by immunoblotting using anti-phospho-Ser9-GSK3β.  
 
Immunoblotting: The method of immunoblotting has been described previously (8, 25). Lysis 
buffer was PBS containing 1% SDS, 1mM PMSF, 2μg/ml pepstatin, 20μg/ml aprotinin, 30μg/ml 
bacitracin, 1mM orthovanadate and 5mM NaFl. Protein concentrations were determined using the 
Lowry method and after appropriate dilution into Laemmli buffer, equal amounts of protein/lane 
were loaded for resolution by SDS-PAGE and subsequent transfer onto nitrocellulose. Proteins 
were immunoblotted with specific primary antibodies and detected using horseradish peroxidase–
conjugated secondary antibodies and chemiluminescence. Equivalence of protein loading was 
routinely controlled by both Ponceau S staining and immunoblotting with anti-β-actin. Scanned 
images of immunoblots were analyzed using AIDA Image or Scion (NIH) Image software.  
Representative images of immunoblots are shown. 
 
 
 
RESULTS 
 
PI3K-GSK3β axis signaling by T-cad in HUVEC 
T-cad upregulation exerts stimulatory effects on PI3K/Akt pathway (8), one of the main signaling 
cascades modulating GSK3β activity in mammalian cells (14, 15). To examine participation of 
GSK3β in T-cad-mediated signaling in human umbilical vein endothelial cells (HUVEC) we first 
determined the effect of T-cad overexpression on phosphorylation of GSK3β on ser-9 
(pser9GSK3β). Adenoviral mediated overexpression of T-cad in HUVEC (T-cad+) results in 
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hyperphosphorylation of GSK3β (Fig. 1A); this was true for both HUVEC cultured under normal 
growth conditions and following serum-deprivation, although in the latter case levels of 
pser9GSK3β were markedly lower (Fig. 1A). As reported for Akt ((8); and included herein as 
experimental control), the effects of T-cad on pser9GSK3β were dependent upon PI3K (Fig. 1B). 
Inclusion of PI3K inhibitor LY294002 under normal culture conditions reduced pser9GSK3β to 
comparably low levels in Empty-vector (E) - and T-cad (T+) - transduced cells. Sensitivity of T-
cad-dependent ser9GSK3β phosphorylation to PI3K inhibition indicates that the ability of T-cad to 
modulate GSK3β activity is independent of canonical Wnt signaling. 
 
T-cad expression level affects accumulation of active β-catenin  
Since T-cad overexpression increases cell cycle progression and proliferation of HUVEC (7) and 
because β-catenin has been shown to be one of the characteristic mediators of GSK3β actions in 
the nucleus, we hypothesized that T-cad might affect the activity of β-catenin. We performed 
immunoblotting using anti-catenin antibodies that distinguish between total cellular β-catenin or 
active (unphosphorylated) β-catenin (30).  Whereas total β-catenin levels were similar between 
T-cad+- and E-HUVECs, levels of active β-catenin were elevated in T-cad+-HUVEC (Fig. 2A). 
Immunofluorescence microscopy using anti-active β-catenin (ABC) revealed a higher degree of 
cells positive for nuclear β-catenin in T-cad+-HUVEC as compared to E-HUVEC (35% vs. 6%, 
P<0.001, Fig. 2B).   
 
To confirm the specificity of T-cad effects on GSK3β phosphorylation and nuclear accumulation 
of active β-catenin we examined HUVEC in which T-cad expression was either depleted 
(siRNA-mediated) or overexpressed (adenoviral-mediated). Akt phosphorylation on ser-473 
(pser473Akt) in T-cad-depleted HUVEC was additionally evaluated since we previously examined 
only consequences of T-cad overexpression (8). In T-cad-siRNA-transduced HUVEC, levels of 
pser473Akt,  pser9GSK3β and active β-catenin  were significantly reduced compared with control 
siRNA-transduced HUVEC (Fig. 3A). This profile is reciprocal to that observed in T-cad 
overexpressing HUVEC in which levels of pser9GSK3β, active β-catenin and pser473Akt were 
significantly higher than in control empty-vector transduced HUVEC (Fig. 3B). Incubation of 
HUVEC with agonistic anti-T-cad antibodies against the first domain, mimicking homophilic 
ligation (5), also increased levels of pser473Akt, pser9GSK3β and active β-catenin (Fig. 3C). Levels 
of total β-catenin, GSK3β and Akt were not affected by depletion or overexpression of T-cad or 
by inclusion of antibodies.Taken together these data unambiguously demonstrate modulation of 
Akt and GSK3β axis signaling and levels of active β-catenin by T-cad.  
 
To examine the dependence of T-cad-induced active β-catenin accumulation upon GSK3β 
inactivation we compared HUVEC after transduction with T-cad-containing (T-cad+) or empty 
adenovectors (E) and/or with adenovectors carrying kinase mutant GSK3β (KM), constitutively 
active GSK3β (S9A) or wild type GSK3β (wt). Cell lysates were immunoblotted for total and 
active β-catenin and for total and pser9GSK3β (Fig. 4A). Equivalent signal intensities for total 
GSK3β in KM-, S9A- or wt-transduced HUVEC indicated equivalent expression of GSK3β 
protein. Compared with E-HUVEC, and as expected (13, 31), levels of active β-catenin were 
elevated in KM- and wt-transduced HUVEC and reduced in S9A-transduced HUVEC. Levels of 
active β-catenin in T-cad+-, KM- and wt-transduced HUVEC were comparable. In T-cad++KM 
and T-cad++wt co-transduced HUVEC the levels of active β-catenin and pser9GSK3β were higher 
than those in singly-transduced HUVEC (Fig. 4B C). These additive effects were not present in 
E+KM or E+wt co-transduced HUVEC. Most importantly, co-transduction of T-cad+-HUVEC 
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with S9A abrogated the stimulatory effects of T-cad on both pser9GSK3β and active β-catenin and 
(c.f. T-cad++S9A vs. T-cad+, Fig. 4B C). These data support that GSK3β underlies accumulation 
of active β-catenin induced by T-cad.   
 
To determine whether the effect of T-cad on nuclear accumulation of active β-catenin is 
functionally relevant we performed reporter gene analysis using a BAT-lux plasmid, a β-catenin-
specifically driven lymphocyte enhancer-binding protein/T cell factor (Lef/Tcf) reporter construct  
(32). T-cad- and empty- adenovector-infected HUVEC were co-transfected with BAT-lux or 
empty plasmids and with pRLTK plasmid constitutively expressing Renilla luciferase as internal 
control. Lef/Tcf promoter activity in T-cad+-HUVEC was greater than in control E-HUVEC (Fig. 
5A).  To obtain additional evidence that T-cad increases β-catenin activation of Lef/Tcf 
transcription factors we investigated expression of cyclin D1, a key transcriptional target of β-
catenin/Lef/Tcf (33). Immunoblotting and quantitative RT-PCR experiments demonstrated 
elevated levels of cyclin D1 protein (Fig. 5B) and cyclin D1 mRNA (Fig. 5C), respectively, in T-
cad+-HUVEC.   
 
T-cad effects on proliferation and survival are dependent upon GSK3β inhibition 
We have previously reported that T-cad upregulation increases cell cycle progression and 
proliferation under normal culture conditions (7) and also enhances survival under conditions of 
stress induced by serum-deprivation (8). Here the possible role of GSK3β in these functional 
responses was investigated using HUVEC transduced with T-cad and/or the various GSK3β 
vectors. Figure 6A shows proliferation profiles of singly transduced HUVEC; whereas T-cad 
transduction increased proliferation (vs. Empty) GSK3β−KM or GSK3β−wt had no effect and 
constitutively active GSK3β-S9A was inhibitory. Co-transduction with both T-cad and 
constitutively active GSK3β-S9A genes completely abrogated stimulatory effects of T-cad on 
cell proliferation (Fig. 6B; c.f. T-cad++S9A vs. T-cad+).  Apoptosis induced by serum deprivation 
was similarly reduced in GSK3β−KM-, GSK3β−wt- and T-cad+-HUVEC (Fig. 6C; vs. Empty). 
Co-transduction with both T-cad and constitutively active GSK3β-S9A abolished the ability of T-
cad to protect cells from apoptosis induced by serum deprivation (Fig. 6C; c.f. T-cad++S9A vs. T-
cad+). Proliferation and survival parameters in Empty+GSK3β−KM, Empty+GSK3β−wt or 
Empty+GSK3β-S9A co-transduced HUVEC were not different than those in HUVEC singly 
transfected with GSK3β−KM, GSK3β−wt or GSK3β-S9A, respectively (data not shown).    
Taken together these data indicate that the ability of T-cad to induce inhibition of GSK3β is 
requisite for its ability to stimulate proliferation and protect from apoptosis 
 
ILK is a mediator of T-cad signaling  
In vitro, ILK  can serve as a membrane-proximal upstream PI3K-dependent modulator of key 
signaling molecules crucial for cell survival, cell proliferation and the process of angiogenesis, 
including Akt and GSK3β  (17, 34-36). Since T-cad expression affects both Akt and GSK3β 
activities, and in a PI3K-dependent manner, we considered the possible involvement of ILK in T-
cad-induced effects.  
 
We first examined ILK-activity in E-HUVEC and T-cad+-HUVEC by pull-down (anti-ILK) 
kinase assays with GSK3β fusion protein as substrate and detection of pser9GSKβ3 by Western 
blotting. Phosphorylation of GSK3β on ser-9 was markedly greater with ILK-immunoprecipitates 
from T-cad+-HUVEC than E-HUVEC; pser9GSKβ3 was not detected when ATP was omitted 
from the assay buffer, thus excluding possible contribution from endogenous pser9GSKβ3 (Fig. 
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7A). The differential in ILK activity between T-cad+-HUVEC and E-HUVEC is also unlikely to 
be explained by any difference in levels of ILK protein since ILK immunoreactivty in whole cell 
lysates was similar. These experiments indicate that T-cad can “activate” ILK. 
 
We next examined the consequences of ILK knock-down on downstream signaling pathways 
affected by T-cad. Western blot analysis revealed that transfection of HUVEC with ILK siRNA 
suppressed ILK expression up to 90% after 72 hrs compared to control siRNA transfected cells 
(Fig. 7B). Silencing of ILK expression resulted in a striking reduction in levels of pser473Akt, 
pser9GSKβ3 and active β-catenin in both E- and T-cad+-HUVEC, and a loss of any differential in 
these parameters between E- and T-cad+-HUVEC (Fig. 7B). Additionally, silencing of ILK 
expression abolished the ability of T-cad to protect cells from apoptosis induced by serum 
deprivation  (Fig. 7C). These data show that ILK mediates T-cad induced signaling and is an 
essential component of the T-cad signaling cascade.  
 
T-cad associates with ILK 
Since both T-cad (23) and ILK (37) are located within raft membrane domains the ILK-
dependent activation of signaling by T-cad may involve some association or co-localization. To 
investigate this possibility we performed co-immunoprecipitation studies on E- and T-cad+-
HUVEC.  T-cad was found to be specifically present in anti-ILK immune complexes, and at 
higher levels in T-cad+-HUVEC than in E-HUVEC (Fig. 8A). Confirmation of the putative 
association between ILK and T-cad by reverse immunoprecipitation with anti-T-cad antibodies 
was not possible since neither our own affinity purified anti-T-cad antibodies nor commercially 
available anti-T-cad antibodies were efficient in immunoprecipitating T-cad. Confocal 
microscopy was applied to further examine the association between ILK and T-cad.  
Immunofluorescence was performed after wounding of subconfluent monolayers in order to be 
able to examine protein localization in both spread and migrating cells. Two different anti-ILK 
antibodies (clone 65.1, Sigma-Aldrich and clone 65.1.9, Upstate Biotechnologies) were tested. 
The typical staining pattern for T-cad in HUVEC, namely a global and punctuate localization 
over the entire cell body and an enrichment within lamellipodia of migrating cells (Fig. 8B, 
middle panels) has been described previously (28). In HUVEC the staining pattern for ILK using 
either of the anti-ILK antibodies was mostly fibrillar over the cell body and with punctuate 
localization at sites of focal adhesion (Fig. 8B, left panels). In our analyses we additionally 
observed a pronounced enrichment of ILK within lamellipodia of migrating cells where it co-
localized with T-cad (Fig. 8B, right panels).  
 
DISCUSSION 
 
This study has identified T-cad as a novel ILK-activating protein in HUVEC and demonstrated 
that ILK is an essential proximal mediator for GPI-anchored T-cad-dependent signal transduction 
via Akt and GSK3β in HUVEC. To our knowledge, this is the first demonstration that ILK can 
function as a regulator for signaling by GPI-anchored proteins. We also demonstrate for the first 
time that alterations in T-cad expression can affect levels of active β-catenin and that T-cad can 
induce an ILK-GSK3β-dependent increase and nuclear accumulation of β-catenin which interacts 
with Lef/Tcf transcription factors to activate target gene expression. This represents a novel 
mechanism (i.e. independent of both canonical Wnt and classical cadherin pathways) for 
controlling cellular β-catenin activity by GPI-anchored proteins. Signaling by T-cad via 
ser9GSK3β  phosphorylation is pivotal to its stimulatory effects on EC proliferation and survival. 
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Unequivocal signaling of T-cad through Akt, GSK3β and subsequently β-catenin in HUVEC was 
demonstrated using a variety of experimental approaches including pharmacological inhibition of 
PI3K, adenoviral mediated overexpression of T-cad and inhibition of T-cad expression by RNA-
interference. Collectively the experiments show that alterations (increase or decrease) in T-cad 
expression in HUVEC modify (increase or decrease, respectively) the phosphorylation status of 
Akt and GSK3β and the level of active β-catenin, and that the effect of T-cad on these signaling 
effectors is dependent upon PI3K activity. Complete abolition of T-cad induced active β-catenin 
accumulation following co-transduction with constitutively active GSK3β mutant (GSK3β-S9A) 
demonstrates that the stimulatory effect of T-cad on active β-catenin accumulation in HUVEC 
was dependent upon GSK3β inhibition.  
 
Phosphorylation of Akt and stabilization and nuclear translocation of β-catenin as a consequence 
of GSK3β phosphorylation are the two main pathways that regulate cell survival and proliferation 
(14, 15, 38-42). We have previously proposed that upregulation of T-cad under conditions of 
oxidative stress functions to protect HUVEC from apoptosis via enhanced survival signaling 
through Akt/mTOR (8). Here we show that transduction of HUVEC with constitutively active 
GSK3β mutant (GSK3β-S9A) completely abrogated pro-proliferative and anti-apoptotic effects 
of T-cad indicating that signal transmission via GSK3β inactivation is also important for T-cad 
modulation of EC growth and survival functions.  
 
Interestingly when wtGSK3β was co-transduced with T-cad the measured parameters for active 
β-catenin and proliferation resembled those found in HUVEC  co-transduced with T-cad 
andGSK3 β kinase mutant KM, indicating a similar decrease in kinase activity.  This would be 
consistent with the high ratio of pser9GSK3β/total level of phosphorylated GSK3β following 
overexpression of wt GSK3β.  Furthermore, since parameters in the case of wtGSK3β /empty 
vector-co-transduced HUVEC were not different from HUVEC transduced with only wtGSK3β it 
is possible to speculate on either an additive effect of endogenous and transduced GSK3β 
phosphorylation or a higher recruitment and inactivation GSK3β via the T-cad/ILK/Akt signal 
relay in T-cad overexpressing cells. Reported effects of overexpression of wt GSK3β are variable 
and it is unclear whether one can predict increased enzymatic activity (like constitutively active 
mutant S9A) or decreased activity (like dominant negative mutant KM) on the basis of changes 
in GSK3β phosphorylation status. It has been shown that overexpression of leads to increased 
GSK3β phosphorylation but an increase in parameters of GSK3β enzymatic activity (31, 43, 44). 
On the other hand it has also been shown that overexpression of wt GSK3β is accompanied by a 
decrease in GSK3β phosphorylation and an increase of parameters of GSK3β enzymatic activity 
(45). A further study did not examine phosphorylation but found functional equivalence between 
control and wt-GSK3β –transfected cells (43).  Additional discrepancies also evidently exist with 
respect to levels of total GSK3β (vs. Control empty vector) whereby Rossig et al., (44) and Gong 
et al.,(43)  reported increased levels (as expected) whereas Hashimoto et al.,(31) and Salas et al., 
(45) reported no change.  
 
That T-cad expression could affect levels of active β-catenin was unexpected. Classical 
cadherins, including VE- and N-cadherin in endothelial cells, are recognized to function as 
modulators of β-catenin signaling, by regulating the availability of free β-catenin for nuclear 
translocation (40-42, 46). The intracellular domains of classical cadherins such as N- and VE- 
cadherin interact with β-catenin, γ-catenin and p120ctn to assemble the cytoplasmic cell adhesion 
complex that is critical for the formation of extracellular cell-cell adhesion. β−catenin and γ-
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catenin bind directly to α-catenin, which links the cytoplasmic cell adhesion complex to the actin 
cytoskeleton. Disruption (via loss of cadherin) or alterations (via phosphorylation) of interactions 
between β-catenin and cadherins not only alters intercellular adhesions but can also regulate 
levels of the availability of β-catenin for nuclear translocation (40-42, 46). GPI-anchored protein 
T-cad does not possess the necessary cytoplasmic domain to effect a direct physical association 
with either β-catenin or other intracellularly located molecules (e.g. GSK3β) that may regulate β-
catenin availability (20).  Thus, T-cad effects on accumulation and nuclear translocation of active 
β-catenin must necessarily proceed via some proximal molecular mediator that couples T-cad 
induced signal transmission to intracellular effectors. 
 
ILK is a ubiquitously expressed protein composed of four ankyrin repeats, a pleckstrin homology 
phospholipid-binding motif, and a C-terminal Ser/Thr kinase domain. A key function of ILK is to 
provide a molecular scaffold for the assembly of proteins involved in connecting integrins and 
growth factor receptors to the actin cytoskeleton  (47-52). Furthermore, and although controversy 
exists as to whether ILK is a bona fide kinase, it can also regulate the activities of key signaling 
components (e.g. Akt and GSK3β) involved in control of cell survival, cell cycle progression, 
cell adhesion, and ECM modification (37, 47-49, 53-55). We considered ILK as a candidate 
molecular mediator for T-cad for a number of reasons.  ILK activity is regulated in a PI3K 
manner (17), it is an upstream regulator of  Akt phosphorylation on ser473 (17, 35, 36, 55-57) 
and GSK3β phosphorylation on ser9 (17, 58, 59), and it has been shown to regulate nuclear β-
catenin and cyclin D1 levels (58), all these properties being common to T-cad induced signaling 
in HUVEC. Functionally, ILK has been demonstrated to be an important regulator of EC 
phenotype and differentiation, adhesion, survival, proliferation and angiogenesis (27, 34, 35, 57, 
60-62), processes also affected by T-cad in HUVEC (4-8, 28). Furthermore, both ILK and T-cad 
are located within plasma membrane raft domains (23, 37), which would facilitate the proximity 
necessary for ILK to serve as a mediator for T-cad. Raft domains function as assembly platforms 
for the dynamic formation of complexes between surface receptors, signal transduction regulators 
and scaffolding proteins, and many of the molecular components regulating cell polarization, 
motility, adhesion, proliferation and survival are associated with plasma membrane rafts (21, 22). 
 
Several lines of evidence in our study support that T-cad indeed utilizes ILK to elicit signaling in 
HUVEC. Firstly, in vitro pull-down assay for ILK (with exogenous GSK3β fusion protein as 
substrate) showed increased activity in immunoprecipitates from HUVEC overexpressing T-cad. 
Secondly, and more importantly, siRNA-mediated ILK depletion completely abolished 
stimulatory effects of T-cad on Akt and GSK3β phosphorylation and accumulation of active β-
catenin. Thirdly, T-cad was present in anti-ILK immune complexes. Fourthly, confocal 
microscopy demonstrated colocalization of T-cad and ILK within lamellipodial extensions of 
migrating cells.  
 
A number of studies have examined the role of ILK in modulating EC function (27, 34, 35, 57, 
60-62). EC-specific deletion in mice and antisense-mediated silencing in zebra fish were both 
shown to confer lethal vascular morphogenic insufficiency in vivo; in vitro analysis of  ILK-
deleted murine EC demonstrated a disruption of integrin-matrix interactions, increased apoptosis 
and a reduction of phosphorylation of Akt on ser473 without a change in phosphorylation of 
GSK3β on ser9 (34). An in vitro study using bovine aortic EC showed that siRNA-mediated 
silencing of ILK increased cell adhesivity to a variety of specific matrix substratum components 
(collagen I, vitronectin, fibronectin, fibrinogen), but impaired cell spreading, migration and 
capillary morphogenesis; these effects were attributed to destabilization of cell-matrix through 
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alterations in surface distribution of αvβ3 and α5β1 integrins and were not accompanied by 
changes in ser473Akt or ser9GSK3β phosphorylation (27). In HUVEC ILK was shown to associate 
with VEGF receptor (57), while transduction with dominant negative, kinase deficient ILK or 
pharmacological inhibition of ILK resulted in inhibition of a number of VEGF-induced responses 
including adherence to collagen 1, phosphorylation of ser473Akt, migration, survival, proliferation 
and capillary morphogenesis (35, 57, 60). In both HUVEC and endothelial progenitor cells ILK 
was plays a key role in cell survival signaling responses (ser473Akt or ser9GSK3β phosphorylation) 
to anchorage deprivation, nutrient deprivation or hypoxia; furthermore using a model of mouse 
hindlimb ischemia ILK was demonstrated to promote endothelial progenitor cell recruitment and 
neovascularization of ischemic tissue (61, 62). Thus, from the above there is a growing consensus 
that ILK plays a key role in the complex process of vascular morphogenesis by influencing 
different mechanisms.  
 
The data herein support a model (Fig. 9) for T-cad-induced signal transduction whereby ILK 
serves as an essential proximal downstream regulator for T-cad to enable inward-directed signals 
via intracellular effectors Akt/GSKβ and subsequent modulation of proliferation and survival 
responses. “Activation” of ILK by T-cad through proximal association is an appealing mediator 
paradigm for PI3K/Akt/GSK3β axis signaling by other GPI-anchored proteins. Whether T-cad 
and ILK constitute part of a larger signaling complex including other transmembrane adapter 
proteins and cytoplasmic signaling molecules requires further investigations.  
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FIGURE LEGENDS 
 
Figure 1: Hyperphosphorylation of GSK3β in T-cad overexpressing HUVEC is PI3K-
dependent. Subconfluent cultures of HUVEC were transduced overnight with empty (Empty or 
E)- or T-cad (T-cad+ or T+)- containing adenovirus and then rinsed with PBS before further 
incubations. Panel A: HUVEC were incubated for 6h in normal serum-containing growth 
medium or serum-free medium (DMEM+0.1% BSA), rinsed with PBS and lysed. Whole cell 
lysates were immunoblotted for pser9GSK3β/total GSK3β (46kDa). Values are mean ± SD (n=4); 
** indicates significant difference (P<0.001) between Empty- and T-cad+- HUVEC. Panel B: E-
and T+-HUVEC were incubated with PI3K inhibitor LY294002 (10mM; Ly) for 6h under serum-
containing (S) and serum- free (SF) conditions. After rinsing whole cell lysates were prepared 
and immunoblotted for T-cad (105 and 130kDa), total/pser473Akt (60kDa) and total/pser9 GSK3β. 
Blots from a single given experiment are presented; comparable results were obtained in at least 3 
other separate experiments. 
 
Figure 2: T-cad overexpressing HUVEC exhibit increased nuclear accumulation of β-catenin. 
Panel A: Whole cell lysates of subconfluent cultures of HUVEC transduced overnight with Empty 
and T-cad- (T-cad+)-containing adenovectors were immunoblotted for total and active β−catenin 
(92kDa). Values are mean±SD (n=5); ** indicates significant difference (P<0.001) between Empty- 
and T-cad+- HUVEC. Panel B: For immunofluoresence Empty- and T-cad+-HUVEC were seeded 
onto gelatine-coated coverslips 12h post-infection and allowed to adhere. After 6h, cells were rinsed, 
fixed with 4% paraformaldehyde and sequentially incubated with anti-active β−catenin and 
secondary anti-mouse Cy3-conjugated antibodies. Samples were analysed under a Zeiss Axiophot 
fluorescent microscope. E1/T+1 and E2/T+2 are representative fluorescence micrographs of Empty/T-
cad+-HUVEC from 2 independent experiments. Scale bar, 50 μm. Values below the micrographs 
represent the degree of nuclear β−catenin translocation calculated as the ratio of those cells with 
nuclei positive for β−catenin to the total number of cells per field. 10 fields per sample were 
randomly selected for analysis. 
 
Figure 3: T-cad expression levels and homophilic ligation modulate PI3K/Akt/GSK3 axis 
signaling in endothelial cells. 
Panel A: Subconfluent HUVEC were transduced with Control siRNA or T-cad specific siRNA and 
after 72h cells were lysed and immunoblotted for T-cad (105 and 130kDa), total/pser473Akt (60kDa), 
total/pser9GSK3β (46kDa), total/active β-catenin (92kDa) and β-actin (43kDa) as internal protein 
loading control. Panel B: Subconfluent HUVEC were transduced overnight with T-cad-containing 
(T-cad+) and Empty adenovirus. Cells were washed once with PBS and lysed. Cell lysates were 
immunoblotted for the same proteins as above. Panel C: Subconfluent HUVEC were incubated with 
purified anti-T-cad antibodies or purified non-immune rabbit IgG (both 10μg/ml) for 6 hours, washed 
once with PBS, lysed and then immunoblotted as above. Each panel presents image sets from a 
single given experiment; given values are levels of pser473Akt, pser9GSK3β and active β-catenin 
expressed relative to levels in the respective controls  (mean±SD, n= at least 3).  
 
Figure 4: T-cad induced accumulation of active β-catenin in HUVEC is GSK3β−dependent. 
Subconfluent HUVEC were transduced overnight with the following adenovectors either alone or in 
combination, as indicated: Empty (E) and T-cad (T-cad+), GSK3β Kinase Mutant (KM), GSK3β 
Constitutively Active (S9A) and GSK3β Wild Type (wt) adenoviruses. Cell lysates were 
immunoblotted for T-cad, total/pser9GSK3β, total/active β-catenin and β−actin. Representative 
immunoblots from one of 3 independent experiments are shown in panel A. Changes in the ratios 
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active β-catenin/total β-catenin (Panel B) and pser9GSK3β/total GSK3β are expressed relative to the 
ratios in E-transduced HUVEC. Values are mean±SD (n=3). * indicates significant difference 
(P<0.01) between T-cad+/wt contransduced HUVEC and either T-cad+- or wt-transduced HUVEC. 
 
Figure 5: T-cad induced elevation in nuclear β catenin in HUVEC is functionally relevant. 
Panel A: Empty and T-cad transduced HUVEC were co-transfected with either pGL3-Empty or 
pGL3-BAT-Lux plasmid and with pRLTK plasmid as internal control. Promoter activity was 
assessed after 48h by dual luciferase assay. Panels B and C: Subconfluent cultures of HUVEC were 
transduced overnight with Empty or T-cad adenovectors, and then processed for either immunoblot 
analysis of cyclin D1 protein (36kDa) expression (Panel B) or RT-PCR analysis of cyclin D1 mRNA 
expression (Panel C). Values are mean±SD (n=3) and ** indicates significant difference (P<0.001) 
between Empty and T-cad infected HUVEC.  
 
Figure 6: T-cad effects on proliferation and survival in HUVEC are dependent upon 
GSK3β inactivation. Subconfluent HUVEC were singly transduced with Empty, T-cad, GSK3β-
wt, GSK3β-S9A or GSK3β-KM adenovectors (Panel A) or co-transduced with Empty or T-cad 
vectors and GSK3β adenovectors as indicated (Panel B). After overnight infection, HUVEC were 
passaged into 96-well plates at 2x103cells/well. Cell enumeration was performed using a Coulter 
Counter after completed adherence (day 0) and thereafter every 24 h for up to 5 days. Data are 
given as mean±SD (n=3; SD’s in range of 5-10%). ξ, Growth of HUVEC transduced with Empty 
vector alone was comparable to Empty/KM and Empty/wt co-transduced HUVEC (individual 
profiles not shown; --X-- in Panel B). For caspase assay (Panel C) subconfluent HUVEC were 
passaged into 96-well plates at 2x104cells/well after overnight transduction. After 24h, apoptosis 
was induced in HUVEC by culture for 6h under conditions of serum-deprivation; caspase activity 
was measured using Homogenous caspases assay kit (Roche Diagnostics). Data are mean±SD 
(n=3). 
 
Figure 7: ILK is a necessary mediator of T-cad signalling. Panel A: ILK activity in subconfluent 
cultures of Empty and T-cad-transduced HUVEC was measured after pull-down from equivalent 
concentrations of cell lysates using anti-ILK (or non-immune IgG as control) as described in 
Methods. Cell lysates were immunoblotted for T-cad, ILK (59kDa) and β-actin. Immune-complexes 
were assayed for ILK activity by incubation in the absence and presence of ATP with GSK3β fusion 
protein as substrate, and subsequent immunoblot analysis of levels of pser9GSK3β. Blots from one of 
two independent experiments are presented. Panels B and C: After overnight transduction of 
subconfluent with control Empty (E) or T-cad (T+) adenovector HUVEC were transfected with 
control and ILK specific siRNAs using siPORT Lipid. Growth medium was replaced after 4h and 
HUVEC cultured for 72 h. Thereafter HUVEC were either lysed for immunoblot analysis of the 
indicated proteins (Panel B), or assayed for survival using homogenous caspases assay kit following 
a 6h period of culture under conditions of serum deprivation (Panel C).  In panel B levels of 
pser473Akt, pser9GSK3β and active β-catenin in T+ are expressed relative to respective levels in E; 
representative blots from one of three independent experiments are presented.   Data are mean±SD (n 
= 3) and significant differences between E-and T-cad+ - HUVEC are indicated with asterisks 
(P<0.001). 
 
Figure 8: T-cad co-associates with ILK in HUVEC. Panel A: Subconfluent HUVEC were 
transduced overnight with Empty or T-cad adenovectors virus, and cell lysates processed for co-
immunoprecipitation with anti-ILK (or non-immune IgG as control). Immunoprecipitates were 
analysed by Western blotting for T-cad. Panel B: For immunofluoresence HUVEC were seeded 
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onto 0.5% gelatine-coated coverslips and allowed to adhere overnight. Cell layers were scrape-
wounded to permit analysis of migrating cells. After 6h cells were washed with PBS, fixed with 
4% paraformaldehyde, 0.1% Triton X-100 and 1% sucrose for 20 mins, followed by a rinse with 
PBS. Cells were sequentially stained with anti-ILK antibodies (either clone 65.1, Sigma (a) or 
clone 65.1.9, Upstate (b)) and anti-mouse Cy2-labelled IgG, followed by a second sequential 
staining with anti-T-cad antibodies and anti- rabbit Cy3-labelled IgG. Samples were analysed 
under a laser scanning confocal microscope. Representative micrographs of single channel 
fluorescence for ILK (green) and T-cad (red) and co-localization fluorescence channel are 
presented. Note co-localization at leading edges of migrating cells (arrows). Scale bar, 20 μm.  
 
Figure 9.  ILK mediates signal transduction by GPI-anchored T-cad. The schematic proposes 
a model for T-cad-induced signal transduction whereby ILK can serve as a proximal mediator 
enabling inwardly-directed signals to intracellular effectors Akt/GSKβ and subsequent 
downstream modulation of proliferation and survival responses. Dashed lines indicate uncertainty 
as to whether ILK directly regulates phosphorylation of Akt//GSK3β and/or whether T-cad and 
ILK constitute part of a larger signaling complex including other transmembrane adapter proteins 
and cytoplasmic signaling molecules. 
 
72
Figure 1
Em
pty
+
T-c
ad
Em
pty
+
T-c
ad
0
1
2
3 **
**
ph
os
ph
o-
G
S
K
3 β
 le
ve
ls
(v
s.
 e
m
pt
y 
ve
ct
or
)
A
pser9-GSK3β
total GSK3β
T-cad
pser9-GSK3β
total-GSK3β
E     T+ E      T+ E      T+ E      T+
S SF S+Ly SF+Ly
B
pser473-Akt
total Akt
Serum Serum-free
73
Figure 2
Em
pty
+
T-c
ad
0
1
2
3
4
**
Ac
tiv
e
β-c
at
en
in
 le
ve
ls
(v
s.
 E
m
pt
y)
Active β-catenin
Total β-catenin
B
Empty T-cad+
A
E1
E2
T+1
T+2
% cells positive for
nuclear β-catenin 6±3 35±9 **
74
Fi
gu
re
3
T-
ca
d
β-a
ct
in
to
ta
l-A
kt
to
ta
l β
-c
at
en
in
to
ta
l-G
SK
3β
A
ct
iv
e
β-c
at
en
in
ps
er
9 -
G
SK
3β
ps
er
47
3 -
A
kt
A
C
on
tr
ol
si
R
N
A
T-
ca
d
si
R
N
A
0.
16
±0
.0
5
1
0.
26
±0
.1
4
1
0.
17
±0
.0
6
1
B
Em
pt
y
T-
ca
d+
2.
41
±0
.3
1
2.
78
±0
.4
1 1
2.
62
±0
.5
C
n/
i I
gG
an
ti-
T-
ca
d
2.
68
±0
.3
2.
94
±0
.5
1 1
2.
85
±0
.4
1
75
Figure 4
T-cad
Active β-catenin
total β-catenin
pser9-GSK3β
total GSK3β
β-Actin
E T-
ca
d+
K
M
S9
A
   
 
w
t
T-
ca
d+
+K
M
T-
ca
d+
+S
9A
 
T-
ca
d+
+w
t
E+
K
M
E+
S9
A
E+
w
t
E +
T-
ca
d KM S9
A w
t
+K
M
+
T-
ca
d +
S9
A
+
T-
ca
d
+w
t
+
T-
ca
d E+
KM
E+
S9
A
E+
w
t0
1
2
3
4
*
*
ac
tiv
e/
to
ta
lβ
-c
at
en
in
(v
s.
 E
)
E +
T-
ca
d K
M
S
9A w
t
+K
M
+
T-
ca
d +
S
9A
+
T-
ca
d
+w
t
+
T-
ca
d E
+K
M
E
+S
9A
E
+w
t
0
2
4
6
8
10 * *
ps
er
9 /
to
ta
l G
S
K
3β
(v
s.
 E
)
A
B
C
76
Figure 5
Em
pty
+
T-
ca
d
0
1
2
3
**
C
yc
lin
 D
1 
pr
ot
ei
n
(r
el
at
iv
e 
ex
pr
es
si
on
)
A
B C
Em
pty
+
T-
ca
d
0
1
2
3 **
C
yc
lin
 D
1 
m
R
N
A
(r
el
at
iv
e 
ex
pr
es
si
on
)
0
2
4
6
8
pGL3/pRLTK
BAT-Lux/pRLTK
Empty T-cad+
**
R
el
at
iv
e 
Lu
ci
fe
ra
se
 U
ni
ts
cyclin D1
β-actin
77
Figure 6
E
m
pt
y +
T-
ca
d K
M
S
9A w
t
+K
M
+
T-
ca
d +
S
9A
+
T-
ca
d
+w
t
+
T-
ca
d
0
25
50
75
100
125 **
ca
sp
as
es
 a
ct
iv
ity
(v
s.
 e
m
pt
y 
ve
ct
or
 c
on
tro
l)
0 1 2 3 4 5
0
10
20
30 T-cad
+
T-cad++S9A
T-cad++wt
T-cad++KM
Emptyξ
Empty+S9A
Day
C
el
l n
um
be
r
(v
s.
 d
ay
 z
er
o)
A B
C
0 1 2 3 4 5
0
10
20
30
Empty
T-cad+
KM
S9A
wt
Day
C
el
l n
um
be
r x
 1
0-
3
(v
s.
 d
ay
 z
er
o)
78
Figure 7
pser9-GSK3β (+ATP)
pser9-GSK3β (-ATP)
T-cad
β-Actin
Empty T-Cad+
Cell lysate
ILK-pull down
activity assay
IgG
total-GSK3β
A
ILK
B
ILK
pser473-Akt
pser9-GSK3β
β−catenin
β-actin
E ET+ T+
Control
siRNA
ILK
siRNA
total-GSK3β
total-Akt
2.68±0.3**
2.94±0.5**
2.66±0.4**
1
1
1
1
1
1
0.95±0.2
1.2±0.3
0.92±0.3
C
control siRNA ILK siRNA
0
50
100
150
E ET+ T+c
as
pa
se
s 
ac
tiv
ity
(v
s.
 E
+c
on
tro
l s
iR
N
A
)
**
79
Figure 8
A non-immune anti-ILK
E             T            E             T
T-cad
n.s.
IgG
B
T-cadILK T-cad +ILK
(a)
(a)
(b)
(b)
80
Figure 9
PIP2              PIP3
Ly29004
PI3K
pser473AktAkt
pser9GSK3βGSK3β
Tcf Lef
β-catenin
Cyclin D1
Proliferation
Integrin
Linked Kinase
T-cadherin
Survival
Cytosol
Plasma membrane
Nucleus
81
 82
3.3. Transcriptional regulation of T-cadherin in endothelial cells 
 
The results of this project have been drafted as a preliminary manuscript. 
 
Characterization of minimal promoter region of T-cadherin in 
endothelial cells.  
 
(The manuscript is appended) 
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 ABSTRACT 
 
T-cadherin (T-cad) an unusual glycosylphosphatidylinositol (GPI)-anchored member of the cadherin 
superfamily is expressed widely in the brain and cardiovascular system, and absent, decreased or 
even increased in cancers. Little is known about mechanisms that control of T-cad expression. This 
study aimed to investigate transcriptional regulation of T-cad in endothelial cells (EC), using human 
microvascular EC line (HMEC-1) as the cell model.  Treatment of HMEC-1 with methylase inhibitor 
5’-azacytidine did not affect T-cad protein expression indicating  epigenetic modification by 
methylation does not regulate T-cad expression in endothelial cells. Conditions of oxidative stress 
(serum-deprivation or presence of H2O2) elevate T-cad protein levels in HMEC-1. Reporter analysis 
using serially deleted T-cad promoter stretches ranging from -99bps to -2304bps located the minimal 
promoter region of T-cad within -285bps from the translation start site. Serum-deprivation or 
exposure to H2O2 increased reporter activity in HMEC-1 transfected with -285bps construct, and this 
could be normalized by inclusion of antioxidant N-acetylcysteine. Gel shift assay using seven 
different oligos starting from -1 to -284bps revealed specific nucleoprotein complex particular to -
156 to -203bps. This was increased using nuclear extracts from oxidatively stressed HMEC-1,   
suggesting -156 to -203bps oligo contains redox-sensitive binding element(s) responsible for 
oxidative stress-induced T-cad upregulation is present between -156 to -206bps from the translation 
start site. Although relevant transcription factors could not be successfully identified, the study 
supports transcriptional regulation of T-cad in endothelial cells by redox-dependent mechanisms.  
 
 
 
 
  
 INTRODUCTION 
 
T-cadherin (T-cad, cadherin-13, H-cadherin) is an unusual glycosylphosphatidylinositol (GPI)-
anchored member of the cadherin super family. Diverse functions have been described for T-cad. In 
the embryonic nervous system T-cad functions as negative guidance cue regulating motor-axon 
outgrowth (1). T-cad has been attributed tumor suppressor functions since in several cancers (e.g. 
breast, lung, colon) loss of T-cad expression correlates with tumour progression, and upregulation of 
T-cad in vitro negatively modulates tumour cell growth and invasion (reviewed in (2)). However, in 
other cancers (e.g. liver, metastatic lung cancer) T-cad expression is elevated (3, 4), and in vitro 
studies suggest a function for T-cad in epithelial-to-mesenchymal transition and promotion of 
invasion (5)). In retinoblastomas T-cad expression is unchanged (6). In the vasculature T-cad is 
upregulated in proliferative disorders such as atherosclerosis and   restenosis (7, 8), and in vitro 
studies a function for T-cad in promotion of cell cycle progression and proliferation of smooth 
muscle cells has been demonstrated (9). T-cad is upregulated in tumor-penetrating blood vessels (5, 
10, 11) and stimulates angiogenesis in vitro and in vivo (12). In vitro studies on endothelial cells 
demonstrate T-cad functions in promotion of proliferation and migration, induction of an angiogenic 
phenotype and protection against oxidative stress-induced apoptosis (12-15). T-cad has also been 
shown to be an low density lipoprotein binding protein (16, 17) and a receptor for adiponectin (11).  
 
Transcriptional regulation of T-cad is complex and poorly understood. T-cad gene has been localized 
on chromosome 16q24 along with a few other cadherins (18). Frequent epigenetic modification of T-
cad promoter by aberrant methylation resulting in allelic loss and diminished expression of T-cad has 
been reported for a variety of cancers including breast (19), lung (20, 21), colorectal (22) (23),  
cervical (24), and nasopharyngeal (25), digestive tract (26, 27), skin (28, 29), pancreatic (30) cancers 
and also chronic myeloid leukemia (31) and malignant B cell lymphomas (32). In PC12 cells T-cad 
has been demonstrated to be a target gene for DNA methytransferase 3B (Dnmt3b), but Dnmt3b-
dependent suppression of T-cad expression occurs via methylation-independent mechanisms (33). 
Other studies have investigated external factors regulating expression of T-cad.  In silico analysis of 
5' upstream promoter region of T-cad gene revealed potential binding sites for the glucocorticoid, 
progesterone and estradiol receptors, and  in osteosarcoma cells glucocorticoids and sex steroids 
were found to variously influence T-cad transcription and/or protein expression (34). 
  
 Arylhydrocarbon (AHR) response elements can also be identified (34, 35) and polycyclic aromatic 
hydrocarbon  AHR agonists were found to suppress T-cad transcript and protein expression in 
vascular smooth muscle cells (35). In a study on prostate development, potential androgen 
responsive elements in the 5' upstream promoter region were suggested as a possible mechanism 
mediating suppression of T-cad gene expression in response to androgen (36). In endothelial cells 
FGF (11) and oxidative stress (15) upregulate T-cad protein expression; mechanisms regulating T-
cad gene expression have not yet been investigated in this cell type.   
 
Here we report that T-cad expression in endothelial cells is not regulated by promoter methylation. 
We characterize the minimal promoter region of T-cadherin in endothelial cells by reporter analysis, 
and using gel shift assay we demonstrate the putative presence of redox-sensitive regulatory 
elements within -156 to -203bps stretch. 
 
 
MATERIALS AND METHODS 
 
Cell lines and cell culture: Human umbilical vein endothelial cells (HUVEC) were purchased from 
PromoCell GmbH (Heidelberg, Germany) and cultured in EC growth medium containing low serum 
(2 %) EC growth supplement (PromoCell). All tissue culture surfaces were pre-coated with 0.1% 
gelatine, and HUVEC were used at passages 2-4 during which expression of markers (von 
Willebrand factor, CD 31, VE-cadherin) for differentiated EC remained steady. Human 
microvascular EC line (HMEC-1) was cultured in the same medium supplemented with 10 % FCS. 
Oxidative stress was induced by incubating cells under serum-free conditions (DMEM+0.1 %BSA) 
or by exposure to 1mM H2O2. N-acetyl cysteine (30 mM) was used as antioxidant. 5’-Azacytidine 
(10μM (Sigma Aldrich) was used as DNA methylase inhibitor. 
 
In silico analysis of T-cad promoter: T-cad promoter sequence from human chromosome16 
(16q24) was downloaded from NCBI database. Upstream of start site (-1 to -2304 bps) was analysed 
using online software to identify putative binding elements for transcription factors based on 
GENOMATIX (www.genomatix.de), TRANSFAC (www.cbrc.jp) and TESS (www.cibl.uppen.edu) 
databases.   
  
  
Preparation of constructs: T-cad promoter sequence from -1 to-2304 was cloned into pGL3 
plasmid (Promega) in between BglII and MluI restriction sites. Various size deletions of promoter 
were generated by PCR with different 5’ primers and a fixed 3’ primer, using genomic DNA of 
endothelial cells as template. The sequence of single reverse primer was 5` TTT GTC CGA CTA 
GAA GCG CCC 3` (-1 to -21) and various forward primers were, 5` GGC AGA GCC TCT CCT 
CAA 3` (-81 to -99), 5` CCT GGT CAT CAG CCT CTA CC3` (-165 to -183), CAA ATG GGA 
TGC CAC CTC 3` (-267 to -285),  5` CGC CAG TCC CCC GTG CAA TTC 3` (-352 to -373), 5` 
GCC CCT CCC TGC CTT CTG CTG 3` (-1149 to-1170), 5` TGT GGG AAA CGT GAG GCT 
AGA TC 3` (-1561 to -1584), 5` GCC AGC AGA ACA GCC CAG GAA AA 3` (-2281 to -2304). 
 
Transient transfection and repoerter gene assay: HMEC-1 cells were transfected with the various 
constructs using Lipofetctamine 2000 reagent (Invitrogen) according to the manufacturer’s protocol. 
105 cells were transfected with 1400ng of either empty pGL3 plasmid or pGL3 with promoter inserts 
and with 100ng of pRLTK plasmid expressing renilla luciferase as internal control. Firefly and 
Renilla luciferase activity were measured 48 hours after transfection using Dual luciferase assay 
system (Promega) in a Luminometer (Berthold Inc).  
 
Preparation of Nuclear Extract: Nuclear extract was prepared by modified protocol formulated by 
Dignam et al (37). Subconfluent HMEC-1 cells were briefly washed with PBS and cells were 
collected by trypsinisation. Cells were washed with PBS followed by incubation with Buffer A 
(25mM HEPES pH7.9,  1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 0.1mM EDTA, 0.1mM EGTA, 
0.1mM Na3VO4 and protease inhibitor cocktail (Roche)) for 30min. on ice. NP-40 was added to cell 
suspensions (final 10%), samples were vortexed for 10sec. and then centrifuged at 12000rpm for 
1min. at 4°C. Nuclear pellets were suspended in cold Buffer C (20mM HEPES pH7.9, 1.5mM 
MgCl2, 420mM NaCl, 0.2mM EDTA, 25% (v/v) glycerol, 0.1mM Na3VO4 and protease inhibitor 
cocktail). Suspensions were subjected to vigorous shaking in a rotary shaker for 1h at 4°C and then 
centrifuged at 12000rpm for 10min. Supernatants were collected, aliquoted and stored at -70°C. 
 
Electrophoretic Mobility Shift Assay: EMSA reactions were performed with following 
oligonucleotides.Oligo -1 to -52 
  
 GTGCAGCCGCGTGCATGAATGAAAACGCCGCCGGGCGCTTCTAGTCGGACAAAATG, 
Oligo-34to-83 AAAGCCTGGCTCCCACGGAAAATATGCTCAGTGCAGCCGCGTGCATGAAT 
Oligo -84 to -139 
TGCTGATCTATTTGGGAAGTTGGCTGGCTGGCGAGGCAGAGCCTCTCCTC, 
Oligo -110 to -
163AGCCTCTACCCAATGCTTTCGTGATGCTGCTGCTGATCTATTTGGGAAGTTGGC,  
Oligo -156 to -203 
GGAAGGAATCCGTCTTGTAAAGCCATTGGTCCTGGTCATCAGCCTCTACCCAATGC, 
Oligo -194 to -243 
GGTGCTCACCCCGTATCTGCCATGCAAAACGAGGGAGCGTTAGGAAGGAATC,  
Oligo -224 to -284, 
5`CAAATGGGATGCCACCTCCGCGGGGCTCGCTCCTCGCGAGGTGCTCACCCCGTATCTG
CCAT.  
 
Oligos were radiolabeled with [α32 P]-dCTP using standard techniques.  Binding reactions were 
performed in a 15μl volume reaction mixture containing 1X binding buffer ( 25mM HEPES pH7.9, 
50mM KCl, 1mM DTT, 1mM EDTA, 10% glycerol), 1μg salmon sperm DNA, 1μg poly dIdC, 1ng 
radiolabeled probe and 15 μg of nuclear extract for 30min. at RT°C.  For competition assays, cold 
oligos or non specific DNA (100X unless otherwise specified) were added 15min. prior to the 
labeled oligos. Samples were loaded onto 4% non-denaturing polyacrylamide gels. Gels were dried 
onto Whatmann paper and visualized by Phosphorimaging. 
 
 
RESULTS 
 
Regulation of T-cad in endothelial cells is not epigenetically controlled  
Upstream of the translation start site of T-cad gene is rich in CpG islands which are frequently 
methylated in cancer cells. The occurrence of partial or complete methylation patterns leading to 
partial or complete inhibition of gene expression has been described (26, 38). We evaluated whether 
epigenetic modification of T-cad promoter by methylation in endothelial cells might play a role in 
regulating their constitutive level of T-cad protein expression. HUVEC, HMEC-1, Melanoma Cells 
  
 (NA8 cell line) and Jurkat cells were cultured for 72 hours in the absence and presence of 5’-
azacytidine (AzaC), a potent inhibitor of DNA methylase, and whole cell lysates subsequently 
analysed for T-cad protein by immunoblot analysis (Fig. 1). AzaC treatment did not alter expression 
of precursor/mature (130kDa/105kDa) T-cad protein in either HUVEC or HMEC-1, suggesting the 
promoter of T-cad is not methylated in endothelial cells since In contrast, in melanoma cells, which 
expressed only the 130kDa precursor form, treatment with AzaC induced a 3-fold increase in 
expression of T-cad. Jurkat cells, transformed T lymphocytes, which did not express T-cad under 
normal culture conditions, synthesized 130kDa precursor form following treatment with methylase 
inhibitor.  
 
Promoter structure of T-cad 
T-cad gene encodes for 2.3kb cDNA and is located on chromosome 16q24. The sequence of T-cad 
promoter with database-identified putative transcription factor binding elements is presented in 
Figure 2. Previous studies have demonstrated that T-cad promoter is TATA-less and a GC-like box 
sequence is located at -266bps (20, 34). Additionally three possible transcription start sites at 
different locations, -73bps, -120bps and -473bps in malignant cells were identified(20, 34). Various 
online databases (GENOMATIX, TRANSFAC and TESS) were utilized to perform pattern searches 
within T-cad promoter for putative transcription factor binding sites. In addition to the previously 
identified Aryl Hydrocarbon Receptor element (AHR) (34, 35), we found Hypoxia Responsive 
Element (HRE) overlapping AHR element at -45bps. Various GGAA/T elements were detected 
starting from -67bps,-119bps, -198bps, -202bps and -277bps. Transcription factors of Ets family 
members, Egr-1, Pea3 and Nuclear Factor of Activated T-cells family members (NFAT) bind to 
GGAA/T element. Software depicted a CAAT box at -154bps and another in reverse strand as an 
inverted CAAT Box at -175bps. CEBP and NF-Y transcription factor family members bind to 
CCAAT element. GATA-1 and Lyf-1 sites were predicted at -227bps and – 115bps, respectively. 
Consensus sequences for Nkx-2, CREB, Cdx, AML-1a, SP1, AP1, Stat5 and MZF1 are located in 
the distal 5` flanking region of T-cad. 
 
Minimal promoter region of T-cad is localized within -285bps 
Serially deleted T-cad promoter stretches were cloned into luciferase reporter plasmid pGL3 basic 
and co-transfected with constitutively active renilla luciferase into HMEC-1. Seven such constructs 
  
 ranging from -99bps to -2304bps were analysed (Fig. 3). The first series of reporter assays were 
conducted under normal serum-containing culture conditions (Fig. 3). The shortest construct from 
the translational start site (-99bps) showed insignificant levels of reporter activity, ruling out the 
presence of any functional regulatory elements within -99bps. Transfection with -173bps construct 
resulted in a ≈ 2-fold increase in reporter activity compared with negative control (empty 
pGL3+pRLTK). Maximum reporter activity, which was ≈ 4 fold above negative control, was 
observed in cells transfected with -285bps construct, thus suggesting the presence of minimal 
regulatory elements within -285bps. Luciferase activity in all further lower deletion constructs up to -
2304bps remained steady at ≈ 2-3-fold.  
 
Since T-cad protein expression in HUVEC is upregulated under conditions of serum-deprivation and 
is mediated by reactive oxygen species (15), we next assessed whether oxidative stress affects the 
above-described pattern of reporter activity in HMEC-1. For these experiments luciferase activity in 
HMEC-1 transfected with each of the seven constructs was determined following a 3h period of 
serum-deprivation. Compared with serum-conditions, reporter activity for -99bps was unchanged, 
there was a small increase (from 2-fold to 3-fold) for -173bps, and a significant elevation (from 4-
fold to 7-fold, p<0.01) of reporter activity was observed for -285bps (Fig. 3). Interestingly, for all 
further lower deletion constructs (-373bps, -1170bps, -1584bps, and -2304bps) there was no 
upregulation of reporter activity under serum-free conditions.   
 
Transcription factor (s) binding element is present on -156 to -203 bps 
To search for physical interactions between regulatory elements and transcription factors, we 
performed gel shift assays with nuclear extracts prepared from subconfluent, proliferating HMEC-1 
and oligos designed from T-cad promoter. Since reporter activity was observed within -173bps and 
elevated in -285bps, we designed seven different oligos starting from -1 to -284bps; oligos were of 
50-60bps length with minimal overlap in order maintain integrity of putative regulatory elements. 
The first series of gel shift assays aimed to detect interactions between the different oligos and 
nuclear extract. Apart from a number of complexes (presumed non-specific) common to all oligos 
we detected a nucleoprotein complex particular to -156 to -203bps oligo (Fig. 4A), which falls within 
the minimal promoter region detected by reporter gene analysis.  
 
  
 To validate the specificity of this nucleoprotein complex, competition assay was performed with 
different concentrations of cold -156 to -203bps oligo. We found a concentration-dependent 
displacement only of the complex particular to -156 to -203bps (Fig. 4B). A further competition 
assay compared displacement of -156 to -203bps oligo by a non-specific oligo within the promoter 
(oligo -34 to -83bps) or by cold -156 to -203bps oligo (Fig. 4C). Displacement was observed only 
with its own cold and not with the non-specific cold oligo, further validating specificity of the 
identified nucleoprotein complex particular to -156 to -203bps. 
 
-285 bps region is modulated by oxidative stress 
We have previously demonstrated that serum-deprivation-induced increase of T-cad protein in 
HUVEC is due to oxidative stress involving NADPH oxidase (15).  Thus having demonstrated a 
serum-deprivation-induced elevation of reporter activity in HMEC-1 transfected with -285bps 
construct (Fig. 3), we next investigated whether -156 to -203bps oligo might contain a redox-
sensitive regulatory element responsible for T-cad upregulation following serum deprivation. 
 
First, whole cell lysates (for Western’s) and nuclear extracts (for EMSA’s) were prepared from 
subconfluent HMEC-1 cultured under serum-free conditions for different times (0-4 hrs). Western 
blot analysis showed an increase in T-cad protein expression in HMEC-1 within 2hrs (Fig. 5A), 
confirming our finding in HUVEC (15). Gel shift analysis using -156 to -203bps oligo revealed an 
increase in formation of the putative specific nucleoprotein complex within 2hrs without a change in 
non-specific complexes (Fig. 5B), suggesting -156 to -203bps oligo contains relevant binding 
element(s). 
 
Next, to validate the oxidative stress-modulated minimal promoter region of T-cad, we examined the 
influence of an external source of reactive oxygen species (ROS) and antioxidants on reporter 
activity of -285bps. HMEC-1 transfected with -285bps construct were cultured for 2hrs either in the 
absence of serum or in the presence of H2O2 and without or with inclusion of N-acetyl cysteine 
(NAC); whole cell lysates and nuclear extracts were prepared. Immunoblot analysis showed an 
NAC-sensitive increase in T-cad protein in HMEC-1 following serum-deprivation or exposure to an 
external source of ROS (Fig. 6A), confirming our observations in HUVEC (15). Both serum-
deprivation and treatment with H2O2 increased reporter activity 2-fold above that under control 
  
 serum-containing conditions, and these oxidative-stress inductions of reporter activity were 
abrogated in the presence of NAC (Fig. 6B). These data suggest regulatory element(s) located in -
285bps are responsible for redox-sensitive modulation of T-cad.  
 
Hypoxia Response Element is located at -45, overlapping with AHR element. To investigate the 
possible functionality of HRE we induced hypoxia in HMEC-1 and HUVEC by treatment with 3% 
oxygen, 150μM cobalt chloride, 100μM deferoxamine and 10 μM cyclopiroxolamine. T-cad protein 
levels in both HMEC-1 and HUVEC remained unchanged (data not shown), and therefore we did not 
pursue gel shift or reporter assays under conditions of hypoxia.  
 
DISCUSSION 
 
This study aimed to investigate transcriptional regulation of T-cad in endothelial cells and is the first 
to identify the minimal promoter region of T-cad gene in endothelial cells. The main findings are: (1) 
epigenetic modification by methylation does not regulate T-cad expression in endothelial cells; (2) 
the minimal promoter region of T-cad is located within -285bps from the translation start site; (3) 
transcription factor(s) binding regulatory element responsible for oxidative stress-induced T-cad 
upregulation is present between -156 to -206bps from the translation start site.  
 
Epigenetic modifications including promoter methylation and histone (de)acetylation are common 
mechanisms for tissue specific gene expression. Some genes (e.g. human tissue transglutaminase 
gene) are regulated by differential methylation whereby  the promoter is hypermethylated and 
silenced in neoplastic cells but hypomethylated in normal cells leading to its constitutive expression 
(39). Other genes (e.g. endothelial nitric oxide synthase gene) are regulated by transcription factor(s) 
for tissue/cell specific constitutive expression whereas the promoter is methylated in all other cell 
types (40). Yet other genes (e.g. E-cadherin) are regulated in a tissue specific manner by either 
promoter methylation or by co-repressors.(41) We found that AzaC did not affect expression of T-
cad in endothelial cells but induced expression in melanoma and Jurkat cells. This suggests T-cad 
belongs to the eNOS-like regulated gene family where it is regulated by transcription factor(s) for 
constitutive expression in EC but suppressed or modulated by promoter methylation in other cell 
types. Expression of T-cad is variable in different in malignant cells. This study shows that 
  
 melanoma cell line expressed only precursor T-cad and this was upregulated upon treatment with 
AzaC, whereas Jurkat cells expressed precursor T-cad only after methylase inhibition. Additionally, 
in a study on hepatocarcinoma (5), of six tested hepatoma cell lines only one (Mahlavu) expressed T-
cad (both precursor and mature) protein, and the rest were differentially (between 4-100%) 
methylated; the effect of methylase inhibition was not investigated.  
 
In contrast to CArG boxes as muscle specific regulatory elements (42), endothelial cell specific 
regulatory elements have not been reported. Spatial and temporal differences in endothelial gene 
expression have been proposed to account for endothelial heterogeneity and vascular diversity (43, 
44). Similarities exist between promoter of T-cad and those of other cadherins and endothelial-
specific genes. For example, T-cad promoter is TATA-less (20, 34) as are E-cadherin (45), P-cad 
(46), and endothelial markers such as  eNOS (47) and VEGF(48). Transcription start sites at 3 
different positions at -73bps, -12bps and -473bps have been located in osteosarcoma cells (34) and in 
lung cancer cell lines (20). We observed minimal promoter activity within -285bps, but not in -99bps 
indicating that the -120bps transcription start site might be functional in endothelial cells. A previous 
study putatively correlated location of AHR element at -45bps with Ahr ligand-dependent repression 
of T-cad in rat smooth muscle cells (35). Since the -99 bps construct did not exhibit any reporter 
activity in endothelial cells, it is possible that differences in regulation of T-cad within different 
constituent cells of the vasculature exist. Support for this assumption derives from observations that 
vasoactive substances such as angiotensin II and thrombin induce T-cad expression in human smooth 
muscle cells but not in endothelial cells (unpublished data).  
 
Endothelial cells transfected with -285bps exhibited a 4-fold increase of minimal reporter activity, 
whereas a 9-fold increase in reporter activity was demonstrated in osteosarcoma cells transfected 
with -434bps (34). Additionally the minimal reporter activity observed within -285bps in endothelial 
cells remained steady with all further deletion fragments tested. An abundance of transcription 
factor(s), different regulatory proteins or malignancy might explain the higher reporter activity in 
osteosarcoma cells. Serum-deprivation- and H2O2- induced reporter activity in cells transfected with 
-285bps could be normalized by antioxidant N-acetylcysteine. Additionally formation of specific 
nucleoprotein complex formation (using -156 to -203bps oligo) was increased under serum-free 
conditions. These data support that the regulatory element present within -285bps/-156 to -203bps in 
  
 endothelial cells is modulated by reactive oxygen species. Under conditions of oxidative stress 
induction of reporter activity was observed only for -285bps fragment but not for further deletion 
fragments, suggesting a possible presence of negative regulatory elements between -285bps to -
373bps that might be functional under oxidative stress.  
 
Specific nucleoprotein complex formation was observed with -156 to -206bps oligo where two 
copies of GGAA (Ets binding element), one GATA and two copies of CAAT are located. The 
presence of GGAA/T elements and their regulation by Ets transcription factor family members have 
been reported upstream of many endothelial cell specific markers such as eNOS (40)(49) VE-
cadherin (50), vWF (51) , Tie1/2 (52) and VEGF receptors (Flk1) (53). The regulation of GGAA/T 
elements by NFAT has also been demonstrated in endothelial cells (54). Endothelin and PECAM 
gene expression are controlled by GATA transcription factors (40). We were unable to determine 
any supershift in gel shift assays using antibodies against Ets1/2, NFAT or GATA (data not shown).  
 
Oxidative stress is a major stimulus for proliferative vascular disorders such as atherosclerosis (55) 
and restenosis (56) and for intraplaque angiogenesis (57). T-cad is upregulated during restenosis (8), 
atherosclerosis (7) and angiogenesis (10) and in vitro studies have demonstrated T-cad to be a redox-
sensitive protein (15). The present study supports transcriptional regulation of T-cad in endothelial 
cells by oxidative mechanisms. While we have been unable to identify a relevant transcription factor 
responsible for T-cad gene regulation in response to oxidative stress, we have located the minimal 
promoter region (-285bps) and revealed a specific redox-sensitive binding element within -156 to -
203bps. 
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 Figure Legends 
 
Figure 1: T-cad is not regulated by promoter methylation in endothelial cells. 
HUVEC, HMEC-1, Melanoma and Jurkat cells were cultured in presence (5-AzaC) or absence (C) of 10μM 
5’-azacytidine for 72 hours. Cells were lysed and processed for Western blotting with anti-T-cad antibodies 
and with anti-Gα as internal control. Representative blots from at least 3 independent experiments are shown.  
 
Figure 2:  5` flanking region of T-cad gene. 
Promoter region of T-cad gene was analyzed using various databases (described in Material and Methods). 
Putative regulatory elements are indicated in bold font. GC like box is located at -266. Ets transcription factors 
binding to GGAA/T elements were found at 67bps,-119bps, -198bps, -202bps and -277bps. CCAAT elements 
were detected at -154 and -175. AHR/HRE elements were detected at 45bps. Arrowhead denotes translation 
start site. Asterisks denote previously reported transcription start sites. -156 to -203 bps responsible for 
formation of specific nucleoprotein complex (see Figure 5) is boxed 
 
Figure 3: Reporter gene analysis for T-cad promoter. 
HMEC-1 were co-transfected with 1400 ng of various deletion fragments cloned in pGL3 and 100ng of 
pRLTK (internal control) using Lipofectamine 2000. Luciferase activity was measured 72 hours after 
transfection. Experiments were performed in HMEC-1 under normal serum-containing culture conditions 
(upper panel) and following 3 hours serum-deprivation (DMEM+0.1% BSA). Data express luciferase activity 
relative to negative control (empty pGL3 + pRLTK) and represent mean ±SD of at least 4 independent 
experiments. The asterisk indicates significant difference (p<0.01) between serum and serum-deprivation 
conditions.  
 
Figure 4: Electrophoretic mobility shift assay reveals formation of specific nucleoprotein complex 
within -156 to -203 bps. 
Panel A:  Gel shift assays were performed with radiolabeled oligos designed from T-cad promoter from -1 to -
284bps and nuclear extracts of proliferating, subconfluent HMEC-1. Samples were resolved on 4% 
acrylamide gels, and nucleoprotein complexes were detected by Phosphorimaging. A representative image of 
3 separate experiments is presented. Apart from complexes common to all oligos (ns), a complex particular to 
-156 to -203bps oligo was observed (indicated by arrow and ?). Differences in intensity of assumed 
nonspecific complexes (ns) are due to non-uniform labeling. 
Competition assay was performed with radiolabelled -156 to -203bps oligo and various concentrations 
(denoted by X) of cold -156 to -203bps oligo (Panel B), or with either cold  -156 to -203bps oligo or non-
  
 specific -34 to-83bps oligo (each at 100X). Double headed arrow indicated specificity of nucleoprotein 
complex.  
 
Figure 5: Oxidative stress induces T-cad protein expression and formation of nucleoprotein complex. 
Cell lysates and nuclear extracts were prepared from HMEC-1 at the indicated intervals after serum 
deprivation. Panel A: Cell lysates were immunoblotted for T-cad and Gα as internal control Panel B: 
Equivalent amounts (15μg) of nuclear extracts were processed for gel shift assay with -156 to -203bps oligo. 
The experiment was performed twice.  
 
Figure 6: Minimal promoter region of -285bps of T-cad is modulated by oxidative stress 
Panel A: Subconfluent HMEC-1 were cultured for 2 hours under serum-free conditions (SF) or in the presence 
of 1mM H2O2 without or with inclusion of 30mM N-acetylcysteine (NAC). Cell lysates were immunoblotted 
for T-cad and Gα. A representative blot of at least 3 independent experiments is shown. Panel B: HMEC-1 
were transfected with -285bps construct.  72 hours post-transfection cells were cultured as for Panel A 
followed by measurement of luciferase activity. Data express luciferase activity relative to activity under 
control serum-containing conditions and represent mean ±SD of 3 independent experiments. The asterisk 
indicates where reporter activity is significantly different (p<0.01) from control serum conditions.  
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4. Key findings and perspectives 
 
T-cad is an unusual member of cadherin superfamily, is widely expressed in cardiovascular system 
and is upregulated during proliferative vascular disorders such as atherosclerosis and restenosis. In 
vitro T-cad facilitates important biological processes such as differentiation, proliferation and 
migration of vascular cells (EC and SMC). T-cad has been proven to possess pro-angiogeneic 
properties in vitro and in vivo. All of the above biological processes are associated with oxidative 
stress and cell death/survival. This dissertation has addressed a number of issues including: 
(1) whether T-cad is modulated under oxidative stress,  
(2) whether T-cad regulates endothelial apoptosis/survival,  
(3) which signaling pathways are activated by T-cad,  
(4) which molecular mediators does T-cad use to effect outside-in signaling,  
(5) characterization of the minimal promoter region of T-cad,  
(6) transcriptional regulation of T-cad. 
 
4.1. Key Findings 
The key findings of this dissertation are schematically summarized in Figure below. 
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We observed an elevation in T-cad levels under condition of oxidative stress induced by serum-
deprivation and H2O2; this response was normalized upon inclusion of an antioxidant, N-acetyl 
cysteine or NADPH oxidase inhibitor diphenyleneiodonium, suggesting T-cad induction by reactive 
oxygen species is NADPH oxidase dependent. Adenoviral mediated overexpression of T-cad 
facilitated EC survival upon induction of apoptosis by serum-deprivation and various apoptosis-
inducing pharmacologicals. Western blot analysis of lysates infected with Empty –adenovirus (E) 
and T-cad adenovirus (T-cad+) resulted in hyperactivity of anti-apoptotic proteins (Akt and mTOR 
target p70S6 kinase) and diminished activity of pro-apoptotic proteins (p38 MAPK and active 
caspase3). PI3 kinase inhibitor, wortmannin, and mTOR inhibitor, rapamycin, normalized anti-
apoptotic effects of T-cad; these data suggest that upregulation of T-cad in response to oxidative 
stress functions to protect EC by concomitant induction of PI3K/Akt/mTOR pathway and 
suppression of p38/caspase3 pathways.  
 
Subsequently we focused on identifying downstream targets of Akt and candidate proximal 
molecular mediators for T-cad. T-cad+-EC exhibited hyperphosphorylation of glycogen synthase β 
(GSK3β) and concomitant nuclear accumulation of active β-catenin, a transcription factor 
regulating cell cycle proteins. Use of various GSK3β-carrying adenovectors (kinase mutant, 
dominant negative or wild type) we demonstrated that T-cad induced nuclear accumulation of β-
catenin is GSK3β-dependent. siRNA mediated knockdown of T-cad resulted in decreased 
phosphorylation of Akt and GSK3β and also in reduced nuclear accumulation of β-catenin. T cell 
factor (TCF) and Leukocyte enhancer factor (LEF) are co-factors for β-catenin; we found that 
luciferase (reporter) activity of TCF/LEF elements in T-cad+-EC was markedly increased as 
compared to E-EC. Cyclin D1, one of the important regulators of the cell cycle is a target of β-
catenin/TCF/LEF transcription machinery; T-cad+-EC showed increased mRNA and protein levels 
of cyclin D1 and increased cell proliferation. In searching for molecular mediators of T-cad we 
considered Integrin linked kinase (ILK) as a putative candidate, because both the proteins are 
located in rafts and ILK acts upstream of Akt and GSK3β in a PI3K-dependent fashion. T-cad+-EC 
exhibited increased ILK “kinase” activity in a pull-down assay. RNAi-mediated knockdown of ILK 
abrogated effects of T-cad on both phosphorylation of Akt and GSK3β and the nuclear 
accumulation β-catenin, suggesting involvement of ILK in T-cad signaling. Confocal microscopy 
studies revealed colocalisation of T-cad and ILK in EC which was most prominent within leading 
edges of migratory cells and at focal adhesions. Anti-ILK immunoprecipitates contained T-cad 
  
 109
indicating the existence of T-cad/ILK complexes, and supporting our hypothesis that ILK can 
function as a proximal molecular mediator for T-cad-elicited PI3K/Akt/GSK3β signaling. 
 
Transcriptional regulation of T-cad in endothelial cells is poorly understood. To characterize the 
minimal promoter region of T-cad, we cloned serially deleted fragments of T-cad promoter 
stretches into luciferase reporter vector (pGL3). Reporter gene analysis exhibited basal levels of 
luciferase activity within -285bps suggesting existence of minimal promoter region with in -285bps 
from translational start site. Oxidative stress elevated reporter activity of -285 bps construct, 
suggesting the minimal promoter region might be responsible for the redox sensitivity of T-cad 
expression. To identify regulatory elements (transcription factors) responsible for T-cad regulation 
gel shift assays were performed using nuclear extracts of EC and various oligos designed from T-
cad promoter region from -1 to -284 bps We identified specific binding of regulatory protein(s) 
between -156 to -203 bps. Nuclear extracts from serum-deprived EC exhibited increased binding to 
-156 to -203 bps oligo, suggesting that the identified nucleoprotein complex could function to 
induce T-cad expression under conditions of oxidative stress. To identify transcription factor(s) 
within the identified nucleoprotein complex we performed pull-down assay using nuclear extracts 
of EC, biotinylated -156 to -203 bps and streptavidin agarose beads. Proteins pulled down were 
subjected to microsequencing by mass spectrometry. Interestingly thioredoxin was found to be 
present. Thioredoxin is a 12kDa protein induced by NADPH oxidase under stress and it acts as an 
antioxidant by facilitating the reduction of other proteins by cysteine thiol-disulfide exchange. 
Following translocation to the nucleus reduces transcription factors enabling their binding to 
regulatory elements. Preliminary data using RNAi technology showed that knockdown of 
thioredoxin abrogates oxidative stress-induced upregulation of T-cad in EC, suggesting that 
NADPH dependent-induction of T-cad involves nuclear translocation of thioredoxin.  
 
 
 
4.2. Perspectives 
 
In the present dissertation we successfully delineated T-cad-induced signaling pathways leading to 
EC survival and proliferation, and studied transcriptional regulation under oxidative stress 
conditions. There are still many issues to resolve.  
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Identification of Transcription factor(s)  
Biotin-streptavidin pull down assay and microsequencing revealed thioredoxin as a putative 
“indirect” regulator of T-cad transcription. This needs to be confirmed. Further it is necessary to 
identify thioredoxin-sensitive transcription factors which would directly modulate T-cad transcript 
expression. The following experimental approaches may be helpful. 
 
1) Immunoprecipitation of thioredoxin from cytosol and incubating with nuclear extracts and 
radiolabelled oligo -156 to -203 followed by performance of gel shift assays to assess whether 
thioredoxin increases binding of unknown TF to regulatory elements located in -156 to -203 
oligo. This would further confirm role of thioredoxin in formation of nucleoprotein complex.  
2) Precipitation of thioredoxin from nucleoprotein complex (i.e oligo -156 to -203 and nuclear 
extracts) and detection of co-precipitated TF using mass spectrometry after comparison of 
differentials between non-immune and thioredoxin pull-down precipitates by silver staining. 
This could identify relevant TF(s). 
3) If any TF is detected by mass spectrometry, supershift assays can be conducted to validate the 
results. 
4) A siRNA approach or use of dominant negative mutants of detected TF(s) with the goal of 
demonstrating suppression of T-cad expression would confirm the functional relevance of the 
identified TF. 
 
Involvement of different signaling pathways/crosstalk in T-cad signaling 
Thus far we have established that T-cad induces PI3K/Akt/GSK3β axis signaling and that this 
participates in the effects of T-cad on EC proliferation and survival. Because T-cad also influences 
other functions of EC (e.g. differentiation, adhesion, migration) it is likely that further signaling 
pathways are activated. Gene expression profile using microarray technology could shed light on 
different pathways involved. An experimental approach to address the issue is as follows. 
1) Extraction of total RNA from ECs either overexpressing T-cad or depleted of T-cad and 
processing for microarray analysis. Modulation of genes due to overexpression or depletion of 
T-cad would be analysed with different softwares classified for different signal transduction 
pathways known to participate in physiological processes such as angiogenesis, proliferation, 
migration and survival.  
2) Validation of microarray data by RT-PCR or by western blotting for particular gene products. 
3) After validation of modulated genes, T-cad-dependent activation/inhibition of the candidate 
signaling pathways can be monitored. 
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4) Ideally, the experiments above should be performed on EC under different conditions, such as 
at quiescence, during active proliferation, active migration or oxidative stress, inter alia. 
 
Signaling pathways induced by T-cad upon LDL binding  
Past studies (using both ligand-blotting cell binding assays) of my laboratory have shown that T-cad 
is an LDL binding protein. Signaling pathways induced by T-cad upon LDL binding are poorly 
understood. My laboratory has further shown that overexpression of T-cad or homophilic ligation 
with antibody against T-cad induces PI3K/Akt/GSK3β pathway signaling. It would be interesting to 
investigate whether LDL binding to T-cad also induces this pathway and/or whether physiological 
processes such as angiogenesis as affected. Experimental approaches to answer the above questions 
would be as follows: 
1) Investigate time- and dose- dependent effects of isolated LDL on signal pathways in ECs that 
either overexpress T-cad or are depleted of T-cad.  
2) ECs that either overexpress T-cad or are depleted of T-cad can be examined for functional 
responses to LDL (e.g. growth, migration, cell survival/apoptosis, differentiation, in vitro 
angiogenesis).  
 
Conditional knockdown of T-cad in endothelium in mice 
Knock-out mouse models are considered a good tool to study physiological significance of a gene. 
The T-cad knock-out mouse does exist (Barbara Ranscht et al., unpublished), but it was not made 
available to us. Since we focus on the role of T-cad in the endothelium and have demonstrated 
proangiogenic properties for T-cad, it would be perhaps more interesting and useful for us create a 
conditional knock-out of T-cad in the endothelium. Such a knock-out model could be created on the 
background of knock-out mice models (e.g. apo E-/-) used to investigate atherosclerotic disease; this 
would be useful for investigating intraplaque angiogenesis. A conditional knock-out of T-cad in the 
endothelium might also be useful for investigating the role of T-cad in tumor angiogenesis, in which 
case tumor cells could be subcutaneously implanted. The approach of conditional knock-out in 
endothelium has been made successfully for genes such as Tubedown-1 protein, VEGF, Focal 
adhesion kinase, β-catenin, inter alia. 
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